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Abstract 
The use of fibrin tissue adhesives in clinical practice has grown over the past 10 years, and there has 
been increased use of adhesives in different surgical subspecialties.  Conventional suture closure of 
periorbital tissues is effective however may result in complications, which has led to the search for 
other techniques and innovations.  Although tissue adhesives have been used in clinical practice there 
is a paucity of randomized controlled studies that have evaluated their advantages and disadvantage in 
surgical practice.   
The goals of eyelid surgery include the restoration of tissue structure and function while 
causing minimal morbidity.  The use of a medical product that induces physiological clotting and 
fibrin formation is appealing in both theory and clinical practice.  However fibrin tissue adhesives 
present disadvantages and complications of their own.  This thesis set out to evaluate the use of fibrin 
tissue adhesives in eyelid surgery and includes a 5-year randomized control study comparing fibrin 
tissue adhesives to suture closure of skin. 
A challenge in the evaluation of eyelid surgery is the definition of a successful outcome.  
Surgical outcomes have traditionally been measured by surgical complications and the need for 
further redo surgery.  Other relevant aspects of surgical outcome that have rarely been evaluated 
include surgical healing and scar formation, asymmetry that is present however not requiring further 
surgery, patient experience and satisfaction.  This research set out to further define outcomes for 
eyelid surgery to enable a more comprehensive and objective evaluation of surgical outcome.   
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1.0!Introduction 
1.1 Background 
The conventional use of sutures for closure of the skin following surgical procedures may be 
associated with suture related complications, increased patient morbidity and additional appointments 
for suture removal.  Suture closure of the periorbital skin may lead to scarring, localized 
inflammation, hypertrophic scarring, asymmetry between the two sides and unhappy patients. These 
complications have led to the search for techniques that close the skin physiologically and improving 
healing (Nesi et al., 1987).  Fibrin tissue adhesives (FTAs) were first made available in the 2nd World 
War for skin grafts although in a simplified form with low fibrinogen levels and limited effectiveness.  
Beginning in the 1980s, commercial adhesives have been developed which have offered advantages 
over conventional surgical techniques with improved surgical outcomes compared to conventional 
techniques (Piechotta and Flemming, 1983, Bruck, 1982, Bruck, 1978). 
Conventional skin closure has been with sutures, and recognized complications include 
infection, granuloma formation, localized trauma, haemorrhage, discomfort, epithelial suture tracts, 
painful suture removal and scarring (Adams and Feurstein, 1986, Lowry and Bartley, 1994).  
Granulomas develop as a foreign body reaction to suture trimmings or other debris trapped in the 
wound during closure and present as nodular thickenings beneath the incision site (Bennett and Matas, 
1982). In addition sutures provide point fixation that provides focal adhesion and not continuous 
adhesion of the wound surfaces that are optimal for vascularisation, reduced haematoma formation 
and postoperative scarring (Gibran et al., 2007).  FTAs were proposed as an alternative method of 
skin closure that triggers a physiological clotting cascade with advantages over conventional sutures 
and staples (Greene et al., 1999, Mandel, 1992, Howell et al., 1995).  FTAs are available as a two 
component system that contains highly concentrated fibrinogen and thrombin.  The mixing of these 
agents immediately prior to use, promoted fibrin cross-linking resulting in physiological haemostasis 
and subsequent wound healing.  The adhesive has been used in a number of surgical subspecialties 
including skin transplantations following burn injuries, neurosurgical closure of dura following 
central spinal fluid (CSF) leaks and the fixation of orbital implants.  Studies have reported advantages 
including improved wound healing, reduced surgical time, complications and reduced pain compared 
to conventional sutures (Greene et al., 1999, Mandel, 1992, Howell et al., 1995).  Anecdotally studies 
have reported improved healing with the use of FTAs although objective evidence and high quality 
research studies have been absent (Foster et al., 2006).  There have been notable disadvantages that 
have included additional cost, risk of dehiscence and the potential risk of infection from the FTA 
product that is derived from human plasma.  There have been few high quality studies evaluating the 
use of FTAs and no prospective randomized studies evaluating the technique following eyelid 
surgery.    
!
!
12!
 Successful outcome following eyelid surgery has been frequently defined by surgical 
outcomes that highlight complications such as infection, delayed healing and the need for redo 
surgery.  However these outcome measures often fail to account for important factors that impact 
surgical outcomes including facial symmetry, scarring and patient satisfaction.  The proportion of 
redo cases are not representative of surgical failure as not all patients need or are prepared to undergo 
further surgery despite an unsatisfactory outcome.  The importance of outcome measures has been 
highlighted by Darzi’s report of “High Quality Care for All” (Darzi, 2007).  The importance of Patient 
Reported Outcome Measures (PROMs) have been recognized as an essential component of measuring 
quality of care and for many surgical procedures including oculoplastic operations remain 
undeveloped (Block, 2006, Langley, 1998, Walburg, 2006).  An objective of this study was to further 
define outcomes for eyelid surgery with particular focus in three specific areas; objective surgical 
measurements, patient satisfaction and the evaluation of standardized postoperative photographs.   
 
!
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1.2 Importance of Research 
The healing response following eyelid surgery and resulting scar formation has marked implications 
to surgical outcomes and patient satisfaction.  Conventional suture closure of the skin has been 
associated with complications related to the non-physiological constitution of the suture material. 
FTAs mechanism of action is to trigger the physiological clotting cascade and result in fibrinogen 
formation.  There are very few randomized studies evaluating the use of FTAs and limitations of past 
studies include both confounding variables and subjective outcome measures.  This study set out to 
evaluate the use of FTA in a randomized control study with a series of objective measures.  This is the 
first randomly controlled study to evaluate the use of fibrin tissue adhesive skin closure for eyelid 
surgery. 
The outcomes following eyelid surgery have traditionally evaluated measurements of the 
eyelids and re-operation rates, these outcomes provide an incomplete evaluation of surgical outcome.  
Patient satisfaction and the masked observation of standard photographs provide a more objective 
assessment of outcome.  This study evaluated three patient outcomes following eyelid surgery with 
the objective of developing a benchmark for future eyelid surgery procedures.   
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1.3 Ptosis 
Eyelid surgery was first described over 2000 years ago in the Susruta, an ancient Indian document 
written in Sanskrit (Kansupada and Sassani, 1997). Arabian surgeons are known to have cauterized 
excess upper eyelid skin to relieve eyelid droop as early as the tenth century (Dupuis and Rees, 1971), 
and the modern-day surgical technique is attributed to Costañares (Costañares, 1951, Rohrich et al., 
2004). 
 
1.3.1 Anatomy of the Eyelid 
The upper eyelid is a mobile structure that protects the eye from injury and enables the even 
distribution of the tears on blinking.  The eyelid consists of three principal layers: anterior lamellar 
(skin, subcutaneous tissue, orbicularis oculi muscle) middle lamellar (orbital septum) and the 
posterior lamellar (tarsal plates, smooth muscle and conjunctiva).   
 
Eyelids 
The skin of the upper eyelid is thin and divided by a horizontal furrow termed the superior palpebral 
sulcus or “skin crease”, and is formed by insertion of the levator palpebral aponeurosis insertion in the 
skin of the upper eyelid (Fengzhi et al., 2009).  In general the skin crease is approximately eight to 
twelve mm in Caucasian and Afro-Caribbean patients.  The upper eyelid meets the lower eyelid at the 
medal and lateral canthal angles that when open form an angle of approximately sixty degrees.  The 
lateral canthus is approximately two millimetres (mm) higher than the medical canthus in Caucasian 
and Afro-Caribbean patients (Snell and Lemp, 1998).  The normal position of the upper eyelid, when 
the eye is open and looking straight ahead, covers the top 2-3mm of the superior cornea.  The position 
of the lower eyelid is independent of the upper eyelid and usually lies at the edge of the cornea termed 
the limbus.   
 The margin of the upper eyelid is approximately thirty mm in length and two mm in 
thickness.  At approximately five mm from the medial angle there is a small elevation termed the 
papilla lacrimalis, this is the entry to canaliculus lacrimalis and the lacrimal drainage channel.  The 
eyelashes are short hairs at the margin of the eyelids that curve in an anterior direction, and are 
arranged in two to three rows.  A sagittal cross-section of the upper eyelids is show in Figure 1. 
!
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In Asian patients there is often an absence of the eyelid skin crease, although the most 
common cosmetic procedure in Southeast Asia is the creation of an upper eyelid skin crease.  
Anatomical studies have identified a lack of the fibrous connection between the aponeurosis and the 
skin in the Asian double eyelid.  Together with the lower positioned orbital septum, prominent pre-
aponeurotic fat and thick orbicularis oculi result in the distinctive eyelid characteristics that are 
different to the Caucasian eyelid (Fengzhi et al., 2009). 
The motor nerve supply to the orbicularis muscle in the upper eyelids is from the buccal, 
zygomatic and frontal branches of the facial nerve, the branches form superior and inferior plexuses 
that innervate the orbicularis muscles (Knize, 2000, Ouattara et al., 2004). 
 
!
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Figure 1 Sagittal Section of the Upper Eyelid 
 
 
a. Skin.  b. Orbicularis oculi muscle.  c. Levator palpebrae.  d. Conjunctiva.  e. Tarsus.  f. Tarsal 
gland.  g. Sebaceous gland.  h. Eyelashes.  i. Small hairs of skin. j. Sweat glands.  k. Posterior tarsal 
glands.  
Acknowledgement for Figure: Grays Anatomy (Gray, 1918) 
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Anterior Lamellar 
The eyelid skin is the thinnest in the body, beneath the skin is the loose subcutaneous tissue of the 
eyelids with increased elastic fibers and minimal fat.  The orbicularis oculi muscle is an elliptical 
muscle that surrounds the globe it is divided into two principal parts the innermost palpebral part that 
is present in the eyelids and an outer orbital part.  The function of the orbicularis oculi is to close the 
eyelids like a purse string.  The muscle is innervated by the facial nerve from temporal and zygomatic 
branches on the deep surface from the parotid area and is not injured by transcutaneous eyelid 
surgery.  The orbicularis muscle is the antagonist to the levator aponeurosis (striated muscle) and 
Horner’s muscle (smooth muscle) which opens the upper eyelids (Albert et al., 2008, Snell and Lemp, 
1998, Bron et al., 1995, Wolff and Last, 1961).   
Middle Lamellar 
The orbital septum forms a fibrous divide between the skin and the orbital cavity, the layer is a 
continuation of the periosteum at the orbital rim.  The septum lies posterior to the medial palpebral 
ligament and anterior to the lateral palpebral ligament, and blends with the levator aponeurosis above 
the superior tarsal border (Fuchs and Duane, 1924).  The orbital septum provides an important 
functional barrier in the eyelid that protects the spread of infection from superficial skin tissues to the 
orbital cavity.  Although preseptal cellulitis is a very common infection of the skin, direct spread 
through the septum to the orbital cavity is rare.  In addition anatomical variation in the position of the 
septum changes the appearance of the periorbital soft tissues.  A low riding orbital septum with the 
orbital fat advancing forward onto the eyelid results in a “full” appearance of the eyelid, conversely a 
high septum may result in a “hollow” appearance of the eyelid as the orbital fat is stopped from 
coming forwards (Bron et al., 1995). 
Posterior Lamellar 
The tarsal plates are a dense fibrous tissue that gives the eyelids a defined shape and structure.  The 
tarsus in the upper lid measures approximately ten mm in height and twenty mm in length and is 
attached to the medially via the medial palpebral ligament to the lacrimal crest and laterally to 
Whitnall’s ligament.  Attached at the superior edge of the upper tarsus are the smooth muscle fibers of 
the levator superior tarsal muscle (Müller’s muscle) and the aponeurosis of the levator palpebral 
superioris.  Within the tarsus are a series of meibomian glands (tarsal glands) that are modified 
sebaceous glands, which consist of a long central canal surrounded by over ten acini.  Their oily 
secretions reduce the evaporation of tears and their gland orifices exit the eyelid just posterior to the 
lashes.  The non-keratinzed squamous epithelium of the tarsal conjunctiva is tightly adherent to the 
upper eyelid and the thin mucous membrane reflects upwards as the superior fornix. 
!
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Levator Complex 
The upper eyelid is elevated by two muscles, the levator palpebral superioris (striated muscle) and the 
superior tarsal muscle (smooth muscle).  The levator palpebral superioris originates from the lesser 
wing of the sphenoid bone, and just above the optic foramen it becomes the levator aponeurosis and is 
approximately fifty-five mm in length (Finsterer, 2003).  The muscle transitions to an aponeurosis 
tendon approximately fifteen mm from the superior tarsus, attaching to the superior transverse 
ligament of Whitnall which acts as a check ligament of the levator (Anderson et al., 1990, Anderson, 
1987, Anderson and Dixon, 1979c).  Whitnall’s ligament extends from the trochlea medially to the 
lacrimal gland capsule and frontal periosteum laterally, and the ligament changes the direction of 
Aponeurotic pull.  The aponeurosis inserts into the anterior aspect of the superior tarsus and sends 
some fibers to the skin to form the upper eyelid crease.  The aponeurosis extends in both medial and 
lateral expansions termed horns which may have a pathological role in upper eyelid retraction in 
conditions such as thyroid eye disease.  The lateral horn indents the lacrimal gland partially dividing 
the gland into a smaller palpebral and thicker orbital portion.  The lateral horn is attached to the 
marginal tubercle of the zygomatic bone and the medial horn fuses with the medial palpebral 
ligament.  The levator palpebral superioris is innervated by the superior branch of the oculomotor 
nerve and elevates the eyelid by twelve to fifteen mm from pull closure to wide-eyed staring (Snell 
and Lemp, 1998, Carraway and Tran, 2009). 
The superior tarsal muscle (Müller’s muscle) is a vascularised smooth muscle that is 
innervated by the sympathetic nervous system.  The muscle originates from the inferior surface of the 
levator aponeurosis and inserts into the superior tarsal plate.  The muscle is approximately twenty by 
twenty mm with a one mm tendon, and elevates the upper eyelid by approximately two mm (Cohen, 
1972, Finsterer, 2003).  Müller’s muscle is responsible for setting the upper lid level in conjunction 
with the levator palpebral superioris.  Increased stimulation of the sympathetic nervous system such as 
stress or adrenaline elevates the eyelid, and corresponding damage to the sympathetic innervation 
results in one to two mm ptosis. 
!
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Eyelid Fat 
The upper eyelid has two pockets of orbital fat, the medial and central fat pads, laterally the pocket is 
filled by the lacrimal gland.  The fat provides a lubricant and glide for the levator aponeurosis.  
Ageing of the tissues, results in atrophy of the fat pads that may result in a deep upper eyelid sulcus 
and sunken appearance.   
 
Figure 2 Elevators of the Upper Eyelid: Sagittal Section 
 
Acknowledgement for Figure: Grays Anatomy (Gray, 1918) 
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Figure 3 Elevators of the Upper Eyelid: Coronal Section 
 
Acknowledgement for Figure: Grays Anatomy (Gray, 1918) 
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Blood Supply of the Upper Eyelids  
The eyelids have a profuse blood supply from the lateral and medial palpebral arteries that form a 
marginal and peripheral arterial arch in the upper and lower eyelids.  The lateral palpebral arteries are 
derived from the lacrimal artery and the medical palpebral arteries from the ophthalmic artery.  The 
venous drainage of the upper medial one thirds of the eyelid is to the submandibular glands and from 
the lateral two thirds to the superficial parotid glands.   
Figure 4 Blood Supply of the Upper Eyelids 
 
 
1. supraorbital artery and vein.  2. nasal artery.  3. angular artery.  4. facial artery.  5. suborbital artery.  
6. anterior branch of the superficial temporal artery.  6.’ malar branch of the transverse artery of the 
face.  7. lacrimal artery.  8. superior palpebral artery.  8’. external arch.  9. anastomoses of the superior 
palpebral with the superficial temporal and lacrimal.  10. inferior palpebral artery.  11. facial vein.  12.  
angular vein.  13. branch of the superficial temporal vein.   
Acknowledgement for Figure: Grays Anatomy (Gray, 1918) 
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1.3.2 Ptosis Definition 
Ptosis has been defined as drooping of the upper eyelid and may be classified by several different 
means including; severity, aetiology, onset and levator function (Beard, 1989).  The exact incidence 
of ptosis is not known, however the condition is common and has equal frequency among different 
races and between the sexes (Finsterer, 2003).   
Elevation of the upper eyelid is the result of the levator palpebrae superioris which is a 
composite muscle made of a striated muscle, a long aponeurotic tendon and a non-striated 
sympathetically innervated (Muller’s) muscle.   The eyelid height is affected by local ocular and 
orbital tissues, as well as conditions effecting the cranial nerve and sympathetic nerve innervation and 
muscles(Jones et al., 1975).   Ptosis may result from a condition affecting the eyelid elevator 
mechanism, in elderly patients there is attenuation of the insertion of the aponeurosis into the tarsal 
plate. 
As the upper eyelid descends it covers the superior aspect of the cornea, restricting the 
superior visual field.   With time the upper eyelid may eventually cover the visual axis resulting in a 
reduced visual acuity.   Patients often describe some variability of the eyelid height, with worsening at 
latter parts of the day that may result from muscular fatigue, myasthenia gravis must be excluded. 
 
1.3.3 Ptosis Causes 
Ptosis may be caused by a large number of different aetiologies including age (involutional), birth 
defects (congenital), reduced innervation (neurogenic), eydlid lumps (mechanical) or other (e.g.  
following intraocular surgery), a comprehensive list is show in Table 1.  The diagnosis of involutional 
ptosis (also called aponeurotic ptosis) is dependent on the exclusion of other causes of ptosis. 
  The upper eyelid may have a false appearance of ptosis which is termed pseudoptosis. This 
must be excluded for the condition to undergo the correct treatment.  Causes of pseudoptosis include 
lid abnormalities, abnormal globe position and a small or sunken globe (Table 1).   
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Table 1 Ptosis- Classified by Aetiology 
Aetiology of 
Ptosis 
Disorders 
Involutional Age-related dehiscence of the levator aponeurosis from the superior tarsal plate 
Congenital Defined as the onset of ptosis within the first year of life.  Idiopathic, localized 
myogenic dysgenesis.  myogenic, neurogenic, mechanical and other causes 
Myogenic Aromatic L-amino acid decarboxylase deficiency, congenital myopathies (central 
core disease), congenital fibrosis of the extraocular muscles, facio-scapulo-humeral 
muscular dystrophy, glycogenosis, mitochondriopathy, myositis, myotonic 
dystrophy, myasthenia gravis, myaesthenic syndrome, oculo-pharyngeal muscular 
dystrophy, orbital rhabdomyosarcoma 
Neurogenic Apraxia of lid opening, blepharospasm (benign, essential), botulinism, botulinum 
toxin therapy, cerebellar vermis hypoplasia, cerebral tumour, cerebral, ocular, 
dental, auricular, skeletal anomalies (CODAS) syndrome, cerebral vasculitis and 
venovascular hypertension, chronic rhinocerebral mucormycosis, cluster headache, 
cortical dysplasia and maldevelopment of the basal ganglia, facial nerve palsy, 
hemifacial spasm, Horner’s syndrome, Marcus Gunn jaw-winking syndrome, 
multiple sclerosis, mycotic meningitis, migraine ophthalmique, optic glioma, orbital 
dermoidal cyst, oxiliplatin neuropathy, paraneoplastic syndrome, Raeder Syndrome 
(acquired Horner’s syndrome with ipsilateral headache), Recklinghausen’s 
neurofibromatosis, rheumatoid pachymeningitis, Riley-Day syndrome, Schwartz-
Jampel syndrome, sleep apnea syndrome, stroke (mesencephalic, hemispheric), 
SUNCT syndrome, syringomyelia, third-nerve palsy (carotid aneurysm, cavernous 
sinus thrombosis, congenital, degenerative CNS diseases, heavy metal intoxication, 
increased intracerebral pressure, trauma, superior orbital fissure syndrome, tumours 
(dermoidal cyst, fibrous tumour, neurinoma, non-Hodgkin’s orbital lymphoma)), 
vascular lesions, Wernicke’s encephalopathy 
Mechanical Scarring, excessive weight—dermatochalasis, eyelid mass (lid tumours: neurinoma, 
neurofibroma), orbital mass 
Traumatic Birth trauma, forceps delivery, corneal abrasion, corneal foreign body, eyelid 
laceration, hard contact lens embedding, orbital fracture (apex or floor), orbital 
haemorrhage, post-cataract ptosis, transorbital penetrating brain injury, trauma to 
the levator aponeurosis 
Miscellaneous Anophthalmos, atopic dermatitis, blepharochalasis, blepharophimosis-ptosis-
epicanthus inversus syndrome (BPES) due to FOXL2 gene mutations, capillary 
haemangioma, carotid aneurysm, carotid cavernous fistula, chalazion, chromosome 
14q terminal deletion syndrome, combined valproate and hydantoin embryopathy, 
craniofacial syndromes, de-novo duplication dup (Xq22.1–q25), distichiasis with 
FOXC2 truncating mutations, double partial monosomy (10p13–10pter and 
Xp11.4–Xpter), Down syndrome, Duane syndrome, exophthalmos, eyelid oedema, 
foetal alcohol syndrome, fibrosis syndrome (CFEOM1 locus on chromosome 12), 
floppy eyelid syndrome, giant papillary conjunctivitis, glaucoma, iris coloboma, 
hypertelorism, mental retardation due to deletion on chromosome 2, Joubert’s 
!
!
25!
syndrome, King-Denborough syndrome, lacrimal gland hemangiopericytoma, 
mandibulofacial dysostosis, mucolipidosis type IV, mycotic aneurysm of the 
internal carotid artery, oculo-facio-cardiac-dental syndrome, orbital artery 
obstruction, orbital or preseptal cellulitis, orbital fat prolapse, orbital fibromatosis, 
orbital Langerhans cell granulomatosis, orbital osteoclastoma, orbital phlegmona, 
Parry-Romberg syndrome, partial trisomy 1q32–qter _pure,_ poorly fitting ocular 
prosthesis, Rubinstein-Taybi syndrome, Smith-Magenis syndrome, Smith-Lemli-
Opitz syndrome, socket contraction, Sturge-Weber syndrome, supernumery 
chromosome 
Iatrogenic Intra-ocular surgery, contact lens wear, chronic inflammation of the conjunctiva 
Pseudoptosis Eyelid abnormalities (ipsilateral excess eyelid skin termed dermatochalasis, 
contralateral eyelid retraction), abnormal globe position (down-turning of the eye 
termed hypotropia) and a small or sunken globe (anophthalmos, enophthalmos, 
microphthalmos, phthisis bulbi, anisometropia) 
Modified from: (Finsterer, 2003, Cetinkaya and Brannan, 2008) 
 
1.3.4 Histopathology of ptosis 
Intraoperative macroscopic evaluation of the levator aponeurosis in patients with involutional ptosis 
may identify a “normal” appearance of the levator with localized dehiscence or fatty degenerative 
change in the anterior part of the levator aponeurosis. These fatty changes may be associated with a 
relatively normal skin crease, more marked ptosis in the medial part of the lid (Collin, 1986). One 
study retrospectively evaluated the patient that required reoperation and found the rate double in the 
patients with fatty levator changes, the reoperation rate was 29% for the fatty-appearing levators and 
14% of the normal-appearing levators (Tucker and Verhulst, 1999). 
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1.3.5 Assessment of Ptosis 
The assessment of a patient with ptosis includes establishing the diagnosis, the aetiology and the 
corresponding development of a management plan.  The evaluation is conducted in a systematic 
manner to ensure accuracy and consistency, including history taking, patient examination and where 
necessary further investigations.   
 
History Taking 
Patients with involutional ptosis often complain of a droopy upper eyelid and a sleepy appearance.  
With increasing severity the descent of the upper eyelid position occludes the superior visual field and 
eventually the pupillary axis.  Patients may tilt their head backwards and adopt a chin-up position to 
improve their sight or use a finger to physically lift the eyelids.  The restriction of superior visual field 
may interfere with the patient’s lifestyle, as patients may have difficulty with driving, reading and 
going up stairs.  Over time, patients may use their forehead muscles to elevate the eyelids this results 
in elevation of their eyebrow and may result in an unusual “surprised” appearance. 
 History taking must include family history, generalized systemic conditions (e.g. diabetes 
mellitus, cardiovascular disorders) and specific neurological disorders (including symptoms of 
fatigue, weakness, dysarthria and dysphasia).  In addition should include the time of onset, associated 
symptoms (e.g. double vision, termed diplopia), trauma and previous contact lens wear.   
 
Examination Findings 
Patients with aponeurotic ptosis, aging of the eyelid tissues and long-term effects of gravity result in 
stretching of the levator aponeurosis and a loss of the muscle tone that can be seen macroscopically 
during surgery.  In addition there maybe disinsertion of the aponeurosis from the superior tarsal plate, 
associated with a characteristic rising and eventual loss of the skin crease.  Involutional ptosis is 
defined by a number of clinical characteristics that are summarized in the table 2.  The classical signs 
of aponeurotic ptosis result from the detachment of the levator aponeurosis from the eyelid tarsus, 
resulting in a high or absent skin crease, increased lid show and deep upper eyelid sulcus.   
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Table 2 Examination Characteristics of Aponeurotic Ptosis 
Assessment Characteristic 
Eyelid Measurements 
Increased upper lid show 
High or absent skin crease 
Deep upper sulcus 
Thinning of the upper eyelid 
Bilateral although maybe asymmetrical 
Exclusion on non-involutional ptosis 
Normal levator function 
Normal ocular movements 
No fatigue 
Normal conjunctival tarsus 
Others  
(not commonly used in clinical assessment) 
 
Normal Muller function (cocaine test) 
Positive finger test (feel the edge of the ptosis with 
the tip of the finger on the upper eyelid during 
elevation) 
Iliff’s Sign: (Positive, if when the eyelid is everted it 
does not flip back to the same position on upgaze) 
(Anderson and Dixon, 1979a, Finsterer, 2003) 
 
The diagnosis of involutional ptosis requires the exclusion of other causes through assessing levator 
function, ocular movements and slit lamp biomicroscopy.  Ocular movement examination requires 
cover tests, pursuit, saccades, test for jaw-winking phenomena and fatigue on upgaze (Shields and 
Putterman, 2003).  For example the presence of diplopia, fatigue on upgaze or slowed saccades is 
suggestive a myogenic cause for the ptosis and would require further evaluation of retina for 
pigmentary retinopathy and systemic assessment.   
Ophthalmic examination of patients with ptosis requires a thorough evaluation including 
generalized head position, eyelids and orbits assessment.  Examination of the eyelids includes 
assessment of asymmetry, brow ptosis, dermatochalasis, orbital fat prolapse, eyelid contour and 
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position.  Patients are often unaware of the additional factors affecting the position of their eyelid and 
need education as part of the management discussion.  Evaluation of the conjunctiva, tarsal plates, 
superior and inferior fornices is routinely assessed.  The visual acuity and visual fields should be 
recorded and may be necessary to justify surgical intervention. 
Examination should include assessment for dry eye, exposure keratopathy and the ocular 
protective mechanism including orbicularis oculi strength and Bell’s phenomenon, corneal sensation 
and tear film adequacy.  Schirmer’s test can be useful to make the diagnosis of dry eye and for 
evaluating the level of severity.  Surgical management of ptosis results in increasing the patient’s risk 
of postoperative dry eye.  
The levator function is an important measure of the eyelid that aids both establishing the 
diagnosis and choosing the appropriate management plan.  The levator function is defined as the 
distance measured from the upper eyelid margin looking in maximal downgaze, to the position of the 
upper eyelid margin looking in maximal upgaze without frontalis action.  The levator function is 
graded as excellent (>10mm), good (8-10mm), fair (5-7mm) or poor (1-4mm) (Frueh, 1980, Fuchs 
and Duane, 1924).  The diagnosis of involutional ptosis required an excellent levator function of 
greater than 10mm and any value less than ten mm would suggest the diagnosis of involutional ptosis 
is incorrect. Normal eyelid measurements are shown in Table 3. Although the average eyelid 
measurements are cited in textbooks, there is evidence that the values are affected by age, gender and 
race (Price et al., 2009).  
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Table 3 Eyelid measurements 
Terminology Measurement 
Pupil reflex Midpoint of pupil resulting from shining a torch in 
front of the eye 
Primary gaze Patient looking straight ahead at a torch at a distance 
of approximately 30cm 
Mid-pupillary line Vertical line drawn through the centre of the pupil 
Marginal reflex distance Distance from the upper eyelid to the pupil reflex in 
primary gaze (Normal >2.5mm) 
Palpebral aperture Distance from the upper eyelid to lower eyelid when 
looking in primary gaze 
Levator function Measurement of the upper eyelid from maximal 
looking down to looking up while preventing frontalis 
movement 
Lid show Distance from the skin crease above the eyelid margin 
to the upper eyelid margin 
Skin crease Measurement from the upper eyelid to the skin crease 
with the patient looking down (Normal 10-11mm in 
men, 8-9mm in women) 
Interlid difference The difference between the right and left upper eyelid 
heights when looking in primary gaze 
Lagophthalmos  Measurement of the distance between the upper and 
lower eyelids with the patient closing their eyes 
(Normal: 0mm) 
Bells phenomenon Position of the cornea when the eyes are closed 
(Normal: eyeballs rotate superiorly) 
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Investigations 
The diagnosis of involutional ptosis does not routinely require specific investigations and the 
diagnosis can frequently be made following clinical assessment.  Uncommonly the assessment of 
ptosis patients may require blood tests, CT or MRI imaging, electromyography or muscle biopsy.  In 
patients where a neurological cause is suspected, CT or MRI imaging may be used to exclude a space 
occupying lesion.  In addition antibody assays, electromyography and muscle biopsies may be used to 
exclude myopathies.   
 
1.3.6 Clinical diagnosis of ptosis 
There have been several different definitions of ptosis described in the literature including; a 
measurement of the amount by which the upper eyelid covers the upper corneal limbus, the size of the 
vertical lid fissure (i.e. palpebral aperture) and the distance from the pupil/ light reflex to the upper 
eyelid (i.e. marginal reflex distance).  One study that compared each of the three methods concluded 
that the most useful definition of ptosis is the marginal reflex distance (Small et al., 1989).  Other 
definitions such as those that include the lower eyelid position are influenced by co-morbidity as they 
are affected by sagging or retraction of the lower eyelid which does not necessarily indicate a 
diagnosis of ptosis (Scoppettuolo et al., 2008, Small et al., 1989).   
Table 4 Ptosis Measurements 
Definition Marginal Reflex Distance/ mm 
Normal marginal reflex distance 2.5-5mm 
Ptosis ≤2mm 
Mild ptosis >1mm, ≤2mm 
Moderate ptosis >0mm, ≤1mm 
Severe ptosis ≤0mm 
 
On evaluation of a patient with ptosis, assessment must be conducted to the fellow eye as involutional 
ptosis is frequently bilateral and asymmetrical.  Hering’s law of innervation states that equal and 
symmetrical innervation is sent to paired yoke muscles in the eyes, including the levator aponeurosis.  
When a patient attempts to elevate the upper eyelid of their more ptotic eye, this induces increased 
innervation to both levator complexes, the increased innervation to the contralateral eye that may 
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mask the mild ptosis.  Following surgical correction of the more ptotic eyelid, innervation to the 
levator complex reduces which may unmask the ptosis in the fellow eye.  Bodian  reported a 1mm 
drop in the contralateral eyelid height following ptosis surgery in 10% of patients (Bodian, 1982).  
Preoperative assessment should include manual elevation of the ptotic eyelid, and assessment of the 
fellow eyelid for a drop in height (Erb et al., 2004, Parsa et al., 2001).  Erb at al. evaluated 
contralateral lid height following unilateral ptosis correction and found that a negative Hering test 
could not exclude a contralateral postoperative drop in lid height and suggested that additional factors 
and variability of lid height may limit its usefulness (Erb et al., 2004).  
One large study that looked at a large number of ptosis operations with mixed aetiology found 
the reoperative rate double in the bilateral group (13%) compared to the unilateral (5% group) 
(McCulley et al., 2003). Although this is suggestive of the importance of Hering Law (an 
exacerbation of contralateral ptosis with ipsilateral eyelid elevation) there is a selection bias that may 
influence results e.g. unilateral congenital cases may have more favourable results.  
 
1.3.7 Factors affecting upper eyelid position 
In addition to the upper eyelid complex (levator palpebral superioris and the superior tarsal muscle) 
that sets the height of the upper eyelid, the upper eyelid height may be influenced by the position of 
the brow, the muscle tone or neurological innovation. The upper eyelid height does vary during the 
day, with patients reporting increased ptosis when they are tired as a consequence of muscle fatigue, 
and with some medical conditions.  In this study systemic conditions that are known to effect eyelid 
height and increase height variability were excluded e.g. myogenic causes of ptosis.   
On measuring the eyelid position, there is a known variability that is dependent on the 
examiner described as inter-observer variability of up to 1mm.  One study found that lid 
measurements are generally accurate to 1.5mm in 84% of patients (Small et al., 1989).  In addition the 
same examiner may find different measurements on the same patient, termed intra-observer 
variability.  Frueh and Small have described techniques to evaluate lid parameters in a relatively 
consistent manner to reduce inter-observer and intra-observer variability (Small et al., 1989, Frueh et 
al., 2004b). 
Eyelid height is affected by ocular surface disease which may cause a secondary ptosis.  For 
example chronic inflammation of the tarsal conjunctiva as a consequence of allergy or infection may 
result in ptosis.  In this study to make the diagnosis of involutional ptosis all patients had their upper 
eyelids everted and the conjunctiva assessed.   
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1.3.8 Treatment of Ptosis 
The treatment of involutional ptosis requires surgical intervention unless the patient is unfit for 
surgery.  Involutional ptosis gradually worsens with time and conservative management with “ptosis 
props”, spectacles with a crutch attachment to elevate the eyelid, are rarely used as they have limited 
benefit and fail to correct the underlying pathology of levator dehiscence from the tarsal plate.  The 
surgical techniques that are used to treat ptosis are generally guided by the aetiology and severity of 
the ptosis, the levator function and the surgeon’s personal preference.  The surgery falls into three 
broad categories: external approach (transcutaneous), internal approach (transconjunctival) and 
frontalis suspension (brow suspension). 
 
External Approach 
The early surgery until the 1970s was based upon the preoperative measurements of the levator 
muscle function and the severity of the ptosis, however this technique had unpredictable results with a 
high incidence of overcorrection in up to 50% of cases of involutional ptosis (Berke, 1971, Berke, 
1959). In 1975, Jones et al described repair of the aponeurosis by an anatomical technique, reviving a 
procedure first described by Eversbusch in 1883 (Jones et al., 1975, Eversbusch, 1883).  Although the 
technique has undergone some modest modifications, the technique is the principal surgical technique 
used for the repair of involutional ptosis in the modern era (Anderson and Dixon, 1979a, Harris and 
Dortzbach, 1975, Older, 1978b). The advantage of this technique included that the surgery could be 
completed with local anaesthesia, the levator function action could be intraoperatively assessed and 
the lid height modified accordingly, resulting in vastly improved success rates (Older, 1978a, 
Anderson and Dixon, 1979a). 
The transcutaneous approach involves an anterior skin crease incision, dissection through the 
orbicularis and orbital septum, and identification of the levator aponeurosis.  The aponeurosis is 
sutured to the superior tarsus with mattress sutures, with the surgery under local anaesthesia the height 
of the eyelid can be adjusted intraoperatively resulting in a reduced risk of over or under correction.  
Levator advancement is the most common method of eyelid elevation, the technique allows the 
simultaneous removal of excess upper eyelid skin and skin crease reformation where indicated.   
Levator resection is similar to levator advancement, the excessive tissue of the levator and 
Müller’s muscle is resected from the tarsus and conjunctiva at the superior border of the tarsus 
(Lucarelli and Lemke, 1999, Frueh et al., 2004a).  The effect of the resection is an increased elevation 
of the eyelid so is a more preferred surgical option in cases with reduced levator function.  Increased 
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elevation results in increased risk of postoperative complications such as dryness, exposure 
keratopathy (corneal erosions secondary to dryness) and lagophthalmos (inability to close the eyelids; 
results in increased dryness) (Cetinkaya and Brannan, 2008).  The current trend is towards minimally 
invasive surgery, and a smaller transcutaneous incision less than the standard 20 mm has been used.  
The results from 8-10mm incisions are comparable to conventional technique with advantages 
including a shorter operative time, lower risk of postoperative scarring, however the technique does 
not enable the treatment of dermatochalasis or fat prolapsed at the time of ptosis repair (Frueh et al., 
2004a). 
 
Internal Approach 
The internal approach requires the surgeon to be more familiar with the anatomy of the upper eyelid, 
and is favoured for cases of mild ptosis with good levator function, notably for ptosis resulting from 
Horner’s syndrome (denervation of the sympathetic innervations to the upper eyelid).  Müller’s 
muscle-conjunctival resection (MMCR) was first described by Putterman et al. for the management of 
mild ptosis (Putterman and Urist, 1975).  The technique is relatively straightforward and following 
eversion of the eyelid, a predetermined amount of conjunctiva and Müller’s muscle is excised 
(Putterman and Urist, 1975, Shields and Putterman, 2003).  A further modification of the procedure 
has proposed additional excision of the tarsus for increased eyelid elevation (Perry et al., 2002).  The 
technique is both effective and reproducible for mild ptosis, with a more predictable upper eyelid 
height that external approach levator aponeurosis surgery (Ben Simon et al., 2005, Dresner, 1991).  
The technique is limited by its use for cases with less than 3mm of ptosis, and complications include 
peaked upper eyelid and a small risk of eyelid instability. The technique is not commonly used for 
involutional ptosis as it fails to correct the pathophysiology and the ptosis is likely to reoccur with 
time. 
 Transconjunctival resection (known as Fasanella-Servat) had been reported effective for most 
types of ptosis with a levator function of greater than 8 mm (Fasanella and Servat, 1961).  The 
technique has been described as the simplest procedure for the correction of ptosis and involves the 
excision of tarsoconjunctiva and Müller’s muscle (Betharia et al., 1983).  There is a risk of 
postoperative lid instability from excision of the tarsus, and the excision should be limited to 3mm 
from lid margin (Betharia et al., 1983).   
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Frontalis Suspension 
Frontalis suspension is indicated in patients with poor levator function (<5mm) such as severe 
congenital ptosis and myogenic ptosis.  The technique requires the use of sling material that suspends 
the upper eyelid to the frontalis muscle, with either autologous (e.g. fascia lata) or non-autologous 
(e.g. silicone tubing) material. The technique is not used for the correction of aponeurotic ptosis the 
levator complex of the eyelid is normal.  Although effective in elevating the eyelid, the technique is 
not a preferred surgical technique as it is associated with specific complications including, 
prominence of the sling material, extrusion and poor eyelid contour (Ben Simon et al., 2005, Dresner, 
1991, Park, 2007).   
 
Skin Incision 
Multiple modalities have been used for incising the skin including the traditional scalpel, 
electrosurgery, radiowave, and lasers (Niamtu, 2008). Radiowave (4.0 MHz system; Surgitron, 
Ellman International, Oceanside, NY) and CO2 laser have the benefit of simultaneous incision and 
coagulation.  Although alternatives to the scalpel incision have intraoperative advantages the surgical 
outcomes, including scar formation and healing are similar (Niamtu, 2008).  
 
Contraindications to Surgery 
Relative contraindications for surgery include patients with high risk of postoperative dry eye, 
including those with marked lagophthalmos, poor Bell’s phenomenon, preoperative keratitis sicca, 
loss of corneal sensitivity (Finsterer, 2003). These are uncommon characteristics of involutional ptosis 
and may be suggestive of a different aetiology. There are few absolute contraindications as severe 
ptosis covering the visual axis has marked implications for patient’s general health and risk of an 
adverse event resulting from reduced vision (Fuchs and Duane, 1924, Ritland et al., 2004). 
 
Complications of Surgery 
The complications of ptosis surgery and upper eyelid blepharoplasty are discussed in detail in 2.3.1 
and summarized in table 13. 
!
!
35!
1.4 Upper Lid Blepharoplasty 
The superior periorbital tissues have an important function in facial expression, protection of the 
eyeball and characteristic signs of aging. Ageing of the upper eyelid results from gravitational effects, 
loss of skin laxity and fat prolapse of the upper eyelid. The term dermatochalasis is used when there is 
an increased fold of upper eyelid skin that may impair the function of the eyelid reducing the superior 
visual field and visual acuity, for the condition to be considered debilitating the superior visual field 
will be restricted and may require assessment before surgery. The orbital fat pads of the upper eyelid 
may prolapse through the orbital septum causing focal or generalized bulging of the upper eyelids.  
Conversely atrophy of the orbital fat may result in increased hollowing and prominence of the upper 
lid sulcus (Morley et al., 2009).  
 Evaluation of the upper eyelid and dermatochalasis requires assessment of the eyebrow shape, 
position and symmetry.  Ageing of the brow can result in brow droop, which may be disguised by 
frontalis contraction that elevates the eyebrow above the orbital rim. If the brow position is not 
corrected and the patient undergoes upper eyelid blepharoplasty it may not correct the underlying 
pathology, resulting in a postoperative brow ptosis as a consequence of loss of the stimulus for 
frontalis overaction to elevate the brow. Meticulous assessment is required preoperatively to identify 
brow droop and dual pathology (Gunter and Antrobus, 1997).  
 Traditionally upper eyelid blepharoplasty surgery involved the excision of lax skin and 
muscle of the upper eyelid including a crescent shape of skin and orbicularis muscle and if prominent, 
excision of orbital fat pads (Goldberg, 2000, Ciuci and Obagi, 2008, Seiff, 2002). There has been a 
change in the conceptual understanding of aging of the face, with greater emphasis placed on volume 
replacement and less excision of tissues (Rohrich et al., 2004). Modern technique preserves the orbital 
fat with repositioning to prevent hollowing of the upper eyelid sulcus and a “skeletal” appearance, and 
in some cases the volume of fat has been augmented with autologous fat transfer. 
 The complications of upper eyelid blepharoplasty are similar to those of ptosis surgery (Table 
13). Vision threatening complications are rare following upper eyelid blepharoplasty however can 
result as a consequence of orbital haemorrhage or penetrating globe injury (DeMere et al., 1974, 
Schechter, 1985). The source of orbital haemorrhage following blepharoplasty or ptosis surgery is 
controversial.  The haemorrhage may result from traumatic injury to the intraorbital fat without 
adequate attention to cauterization of vasculature.  Blindness has not been reported to occur with an 
unopened orbital septum, hence without trauma to the intraorbital fat (Lowry and Bartley, 1994).  
Other theories including trauma to the orbital vasculature, postoperative vasospasm and rebound 
haemorrhage following local anaesthesia and adrenaline reabsorption (Lowry and Bartley, 1994).  
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1.5 Fibrin Tissue Adhesives  
1.5.1 Overview of FTAs 
There are two principal types of adhesives that are used in medical practice.  The synthetic adhesives 
(e.g. cyanoacrylate derivatives) are compounds with very high tensile strength that rapidly polymerize 
on contact with substances such as water or blood.  Synthetic adhesives are non-biodegradable and 
induce an inflammatory foreign body response that limits their clinical use.  Fibrin-based adhesives 
are biological agents that have a lower tensile strength and slower polymerization.  Their 
physiological properties make them biodegradable and their use induces only a mild inflammatory 
response, their favourable properties means have a much wider application in medicine (Chan and 
Boisjoly, 2004).  The FTAs may provide a local environment that is more supportive of healing and 
scar remodelling such as cell migration and proliferation (Mogford et al., 2009). 
The first use of fibrin as an adhesive was in World War I to enhance the tissue adhesion of 
skin grafts in soldiers with severe burn injuries, however the low concentration of fibrinogen in 
plasma reduced its effectiveness and viability.  In addition the screening of human plasma for 
infectious diseases was limited and many patients treated with early fibrin sealants became infected 
with viral hepatitis (Jackson, 2001b, Jackson, 2001a, Grey, 1915), Cronkite 1944).  The fibrinogen 
concentration was increased and the FTA reformulated during the 1970s and Tisseel (Baxter AG 
Industries, Vienna, Austria) first became available in Europe in the 1970s.  In the 1980s the Food and 
Drug Administration (FSA) did not approve the licensing of the FTA product because of the 
perceived high associated risk of hepatitis transmission from the pooled human plasma (Jackson, 
2001b, Jackson, 2001a).  In the 1990’s substantial improvements to the formulation were made 
including the addition of aprotinin to slow fibrin clot lysis in addition to general improvements in the 
quality, consistency and cross-reactivity of the human clotting factors (Chan and Boisjoly, 2004, 
Radosevich et al., 1997) and in the US Food and Drug Administration approved it for clinical use in 
2003 (Lee et al., 2009).  
 
1.5.2 Mechanism of Adhesion 
The FTAs mimic the physiological coagulation cascade as show in Figure 5.  FTAs are 
composed of human plasma-derived mixture of thrombin and fibrinogen and result in fibrin clot 
formation.  The coagulation cascade is triggered, factor X hydrolyses prothrombin to thrombin, and in 
the presence of thrombin, fibrinogen is converted to a lose fibrin polymer (Thompson et al., 1988). 
Thrombin activates factor XIII to trigger fibrin cross linking, replicating the common pathway of the 
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coagulation cascade resulting in stable clot formation.  The normal degradation of the fibrin is 
blocked by the addition of aprotinin, a protease.  The aprotinin was originally a bovine product that 
carried an increased risk of allergy, this has been subsequently replaced with synthetic aprotinin.  The 
strength of the adhesion is proportional to concentration of fibrinogen (67-106 mg/ml) which in the 
commercially available products is approximately thirty times normal plasma (Mommaerts et al., 
1996, Batman et al., 2009).  In addition the FTA may promote the formation of a biomatrix scaffold 
that promotes cellular regeneration and wound healing through fibroblast proliferation and collagen 
deposition.  The fibrin and fibronectin crosslinks with tissue collagen, and the fibrin forms covalent, 
hydrogen and electrostatic bonds to the local tissues (Radosevich et al., 1997).  The fibrin sealant 
matrix enables the diffusion of nutrients, cytokines and other molecules required for subsequent 
healing and a scaffold for the in-growth of fibroblasts and capillary endothelial cells (Brown et al., 
1992, Grabosch et al., 1994). 
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Figure 5 Fibrin Tissue Adhesives activate the Physiological Coagulation Cascade 
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1.5.3 Adhesive Properties & Use 
The optimal adhesive for medical use should have characteristics including; good biodegradability, 
tissue compatibility, binding strength, safe and low cost (Mommaerts et al., 1996) (See Table 5).  No 
known adhesive fulfils all of the characteristics, however FTAs have many favourable characteristics 
for medical use; non-toxic, physiological, quick drying, non-inflammatory, high tensile strength and 
straightforward to use.  In addition some publications have proposed that it may reduce operational 
time compared to suture use.  Uses have included the control of haemorrhage in surgical procedures 
involving cardiopulmonary bypass and traumatic splenic haemorrhage (Kram et al., 1991b).  
Documented advantages in facial surgery include reduced oedema and haemorrhage and a shorter 
down-time (Ellis and Pelausa, 1988, Kamer and Nguyen, 2007).  There was no fundamental 
difference in wound healing from fibrinogen and suture fixed facial flaps after extensive skin 
undermining with total reabsorption of the adhesive in less than one week (Piechotta and Flemming, 
1983).  The natural degradation of the fibrin clot may be prolonged with the use of aprotinin and 
increased concentrations of fibrinogen over a period of weeks (Radosevich et al., 1997, Chan and 
Boisjoly, 2004).  FTAs offer the advantage of continuous surface adhesion across the entire wound, 
compared to multiple point suture fixation, and in doing so may reduce the formation of both 
haematoma and seroma complications (Gibran et al., 2007). 
In ophthalmic surgery, FTA has been used following intraocular vitreoretinal surgery.  Suture 
closure of vitreoretinal ports can lead to suture irritation, discomfort, scleral necrosis, granuloma 
formation, wound leakage and postoperative astigmatism.  FTA has been effectively used to close 
scleral and conjunctival wounds in patients, reducing suture related complications and hastening 
postoperative recovery (Batman et al., 2009).  FTA have been used in the management of external eye 
diseases including the treatment of corneal thinning and perforations and ocular surface diseases 
(Lagoutte et al., 1989, Chan and Boisjoly, 2004, Sharma et al., 2003, Duchesne et al., 2001, Sumich et 
al., 2003, Watts and Collin, 1992, Grewing and Mester, 1997). 
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Table 5 Optimal Tissue Adhesive Properties  
Adhesive Properties FTA Sutures Cyanoacrylate 
Adhesives 
Non-Toxic Y Y N 
Quick drying Y - Y 
Non-Inflammatory Y N N 
High Tensile Strength Y Y Y 
Straightforward to use Y Y Y 
Clear to permit vision Y Y N 
Permeable to permit fluids, prevent necrosis N* Y N 
Physiologically dissolve Y N N 
No risk of infection Y** N N 
Accessible +/- Y +/- 
Cost-Effective - Y +/- 
*Very rare reports of skin necrosis with use of FTA (Grossman et al., 2001) , **Small risk of systemic 
infection, screening of products to prevent transmission (Mommaerts et al., 1996), (Forseth et al., 
1992, Panda et al., 2009) 
 
Tissue injury initiates a cascade of local cytokine and growth factor production that leads to localized 
inflammation, granulation tissue formation, re-eptihelialisation and tissue remodelling (Eby et al., 
2001).  In animal models the use of FTA has shown accelerated healing with improved 
revascularization, reduced inflammation and fibrous formation in grafted tissues (Milanov et al., 
2004). There is thought to be an optimal level of wound inflammation that results in an effective and 
uncomplicated healing of a wound.  Some degree of inflammation provides a protective role, 
preventing infection and removing dead material and pathogens, which enabling restoration of normal 
tissue through collagen formation, angiogenesis and tissue remodelling (Chvapil and Koopmann, 
1984, Clark, 1985, Hunt et al., 1984).  Excessive inflammation is through to result in hypertrophic 
scar formation or continued inflammation or localized oedema (Chvapil and Koopmann, 1984, 
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Niessen et al., 1999).  FTAs provide a protective barrier across the wound may function like a fibrin-
rich haemostatic clot and some studies have identified an attenuation of the inflammatory response 
with the use of FTAs. However the evidence is controversial as other studies have identified a mild 
increase in inflammation (Days 5-30) in FTA wounds compared to controls (Eby et al., 2001, 
Scardino et al., 1999).  Studies have identified an increase in the amount of granulation tissue and 
angiogenesis in FTA wounds, which hypothetically increase the oxygen and nutrient support to the 
healing tissue improving the wound-healing process (Dvorak et al., 1987).  
 
There are several types of commercially available fibrin tissue adhesives.  Tisseel (Baxter AG 
Industries, Austria) is a human plasma-derived mixture of thrombin and fibrinogen.  The combination 
of these two products results in fibrin clot formation and effective adhesion between tissue surfaces.  
The Tisseel product does have a risk of hypersensitivity, allergic and anaphylactic reactions, although 
no adverse events of this type were reported during clinical trials.  There have been reports of 
urticaria, pruritus and generalized flushing with skin and subcutaneous tissue use.  Another FTA, 
Crosseal used tranxanemic acid rather than aprotinin, and has subsequently been discontinued and 
reformulated as Evicel (Johnson & Johnson-Wound Management, Somerville, New Jersey)(Lee et al., 
2009).   
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Table 6 Available Commercial FTA products 
FTA 
Commercial 
Products 
Solution Human 
fibrinog
en 
(mg/mL) 
 
Huma
n 
factor 
XIII 
(U/mL) 
 
Human 
thrombi
n 
(IU/mL) 
 
Bovine 
aprotinin 
(KIU/mL) 
 
Virus-
inactivated 
fibrinogen 
 
Virus-
inactivated 
thrombin 
Tisseel, Tissucol 
(Duo 
Baxter-Immuno 
AG, 
Austria) 
Frozen 
solution 
 
70–110 10–50 500 3,000 Two-step 
vapour heat 
at 60°C and 
80°C 
 
Two-step 
vapour heat 
at 60°C and 
80°C 
Tisseel, Tissucol 
(Duo 
Baxter-Immuno 
AG, 
Austria) 
Lyophilizate 70–110 10–50 500 3,000 Two-step 
vapour heat 
at 60°C and 
80°C 
 
Two-step 
vapour heat 
at 60°C and 
80°C 
Tisseel (VH Kit 
Baxter- 
Immuno AG, 
USA) 
Lyophilizate  75–
115 
500 3,000 Two-step 
vapour heat 
at 60°C and 
80°C 
 
Two-step 
vapour heat 
at 60°C and 
80°C 
Beriplast P 
(Aventis 
Behring, 
Germany) 
 
Lyophilizate 90 (65–
115) 
60 
(40–
80) 
500 
(400–
600) 
1,000 Pasteurizatio
n 
(liquid 
solution, 
10 h at 
60°C) 
 
Pasteurizatio
n 
(liquid 
solution, 
10 h at 
60°C) 
Hemaseel (APR 
Haemacure, 
Canada) 
(As Tisseel VH 
Kit 
Baxter-Immuno) 
 
Lyophilizate 75–115  500 3,000 Two-step 
vapour heat 
at 60°C and 
80°C 
 
Two-step 
vapour heat 
at 60°C and 
80°C 
Quixil (Omrix 
Biopharmaceutica
ls SA, 
Israel) 
 
Frozen 
solution 
 
60–100  
 
None  
 
1,000 None 
(tranexami
c acid 
92 
mg/mL) 
treatment 
 
Solvent–
detergent, 
pasteurizatio
n 
 
Solvent–
detergent 
treatment, 
nanofiltratio
n  
Bolheal 
(Kaketsuken 
Pharmaceutical, 
Japan) 
 
Lyophilizate 80 75 250 1,000 Dry heat 
(144 h at 
65°C) 
 
Dry heat (96 
h at 
65°C) 
Biocol (LFB-
Lille, France) 
Lyophilizate  127 11 558 3,000 Solvent–
detergent 
treatment 
 
Solvent–
detergent 
treatment 
VIGuard F.S. 
(Vitex: VI 
Technologies, 
USA) 
 
Lyophilizate 50–95  3–5 200 None Solvent–
detergent 
treatment, 
ultraviolet 
C light 
Solvent–
detergent 
treatment, 
ultraviolet 
C light 
Modified from: (Jackson, 2001a) 
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1.5.4 FTA Risks & Complications 
The potential disadvantage of FTA is that it is a human product that carries a small but inherent risk of 
disease transmission.  The theoretical risk of infection includes blood-borne diseases such as hepatitis 
B and C, and immunodeficiency virus.  Parvovirus B19 transmission has been attributed to the use of 
FTA, although generally a mild infection, it may be more serious in pregnancy and neonates (Hino et 
al., 2000).  Since the publication of the report by Hino et al, manufacturers have eliminated this risk 
by polymerase chain testing for Parvovirus B19 (Jackson, 2001a).  There was a theoretical risk of 
transmission of bovine spongiform encephalopathy from the use of bovine aprotinin, this has been 
reduced with the use of synthetic aprotinin.  The human donors and plasmin product is rigorously 
screened for known diseases and the products undergo several stages of treatment which substantially 
reduces this risk of disease transmission (Lee et al., 2009, Pryor et al., 2008).   The treatments include 
solvent-detergents, vapour heat or pasteurization, followed by additional treatments including dry 
heat, nanofiltration and other viral reduction treatments (e.g. chromatography) (Jackson, 2001b, 
Jackson, 2001a). 
The Preparation of FTAs from plasma requires a series of stages of processing including the 
isolation of clotting constituents and treatment to eliminate risk of infection transmission (Hartman et 
al., 1992, Quick, 1967).  In summary, the donor plasma is centrifuged to produce a precipitate of 
fibrinogen and supernatant of thrombin.  The thrombin is further treated to convert residual fibrinogen 
to fibrin followed by filtered removal of the fibrin.  The use of autologous platelet-rich plasma does 
eliminate the risk of infection transmission and potential allergic response.  The strength of FTA is 
related to the fibrinogen concentration, and inter-patient variability of fibrinogen concentration is a 
source of increased unreliability, and the autologous adhesives have a lower tensile strength that limits 
their use (Mandel, 1992).  The procedure does take longer to process and as a consequence increases 
both costs and time.  Baxter is currently developing a recombinant fibrinogen for commercial use, and 
other proposed modifications include combination of the FTA with antibiotics and bioengineered 
stem cells (Yamada et al., 2003, Marone et al., 1999, Kram et al., 1991a). 
Although the relative costs of FTA has come down over the past decade, the cost remains 
greater than conventional suture closure of the skin.  The upfront cost of suture material does not take 
into account the resources required for a postoperative appointment to remove sutures.  There are 
additional savings that have been proposed by FTAs including reduced complications and time of 
surgery for certain procedures.   
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1.5.5 Cyanoacrylates 
Cyanoacrylates are another type of adhesives that are termed synthetic adhesives.  These adhesives 
are non-physiological and potentially toxic to the human body.  These adhesives have been effectively 
used to close skin following superficial injuries, however the cyanoacrylates are toxic to subcutaneous 
tissues inciting an acute inflammatory response, foreign body giant cell reaction, neovascularisation 
and tissue necrosis (Mommaerts et al., 1996).  In ophthalmology the synthetic adhesives are most 
commonly used in the management of small corneal perforations without loss of tissue, however their 
use is not without potential toxicity (Tseng et al., 1990). Superficial use in the management of eye 
conditions may result in foreign body reactions such as giant papillary conjunctivitis, and corneal 
vascularisation and microbial keratitis (Carlson and Wilhelmus, 1987, Vrabec and Jordan, 1994). 
 
1.5.6 Medical use of FTAs 
The use of FTAs has had applications in other medical specialties including; general surgery, 
cardiovascular surgery, vascular surgery, neurosurgery, thoracic surgery, urologic surgery, 
otolaryngology and plastic and reconstructive surgery (Albala and Lawson, 2006, Lee and Jones, 
2005). 
The use of FTAs in ophthalmic surgery has become increasingly common over the past 5-
years.  Sealants have been used for closure of the conjunctiva (Erbagci and Bekir, 2007), corneal 
surgery (Patel et al., 1993), glaucoma surgery (Seligsohn et al., 2004),  vitreoretinal surgery (Mentens 
and Stalmans, 2007), strabismus surgery(Mohan et al., 2003) and pterygium surgery (Koranyi et al., 
2004).  These studies have identified advantages over previous surgical techniques with less 
postoperative pain, reduced surgical time and an absence of complications relating to suture use such 
as infection, allergy, inflammation and delayed healing (Kavanagh et al., 2009).  FTAs use in 
oculoplastics remains relatively uncommon although the technique has been proposed in eyelid 
surgery including reconstruction, fixation of free skin grafts and severe entropion (Steinkogler, 
1986b).   
Fibrin sealants have been found to offer advantages in facial reconstruction with the use of 
skin grafts, with increased ‘take’ of grafts at infected sites and reduced wound construction (Brown et 
al., 1992, Jabs et al., 1992). The use of FTAs in eyelid surgery has been evaluated in relatively few 
studies (Mommaerts et al., 1996). One study evaluated the used of FTA for skin closure following 
lower lid blepharoplasty found a reduction in operation time, postoperative ecchymosis and 
elimination of painful subciliary suture removal.  These parameters were not objectively evaluated 
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and were reported as subjective comments (Mommaerts et al., 1996).  Brown et al showed that FTA 
applied to sutured skin graft significantly reduced wound contraction (Brown et al., 1992).  Other 
studies have shown that FTA assist topical haemostasis and reduce blood loss as a function of graft 
size (McGill et al., 1997).  No study has investigated their effectiveness in a randomized control 
study. 
 
Table 7 Surgical use of FTAs in Ophthalmology 
Ophthalmology Sub-speciality Surgery Reference 
External Eye Disease Pterygium autografts 
Closure of Conjunctiva 
Corneal perforation & melt 
Limbal cell transplantation 
(Kheirkhah et al., 2008, Bahar et 
al., 2007, Uy et al., 2005, 
Karalezli et al., 2008, Vrabec 
and Jordan, 1994) 
Glaucoma  Management of 
postoperative bleb leaks 
(Seligsohn et al., 2004, Asrani 
and Wilensky, 1996, Valimaki, 
2006, Grewing and Mester, 
1997, Freeman et al., Kahook 
and Noecker, 2006) 
Strabismus/ Vitreoretinal surgery  Closure of conjunctiva (Erbagci and Bekir, 2007, 
Mohan et al., 2003, Dadeya and 
Ms, 2001, Biedner and 
Rosenthal, 1996, Erbil et al., 
1991, Batman et al., 2009, 
Batman et al., 2008) 
Skin reconstruction  
Oculoplastic surgery 
skin grafts, reconstruction (Brown et al., 1992, Steinkogler, 
1986a, Mandel, 1990, Mandel, 
1992, Jabs et al., 1992, 
Steinkogler and Kuchar, 1994) 
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1.6 Surgical Outcomes 
The outcomes of surgery have previously been traditionally evaluated by the recording of eyelid 
measurements and complications following surgery.  Eyelid measurements that quantify ptosis would 
be expected to show improvements following successful surgery e.g. marginal reflex distance, inter-
eyelid difference, and provide objective information that enables the comparison of surgical 
techniques.  However these traditional methods of measuring outcome are with limitations, the 
number of patients willing to undergo further redo surgery is lower that the number of failed 
operations, as not all patients will be prepared to undergo a second operation when they are 
dissatisfied with the first operation.  The Department of Health (DOH) report “High quality care for 
all” by Professor Darzi highlighted the importance of developing greater measures of quality and 
patient reported outcome measures (PROMS) (Darzi, 2007, Horton, 2008). Outcomes for clinical 
management should include aspects of patient experience, safety and greater transparency of 
information through publication.  In this study three outcome measures were developed that are 
detailed in section 1.7. 
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1.7 Research Objectives 
This study sets out to evaluate the quality and effectiveness of skin closure following eyelid surgery 
with conventional sutures compared FTA.  In addition the study aimed to define a benchmark by 
which outcomes following eyelid surgery can be measured.  Three patient outcome measures were 
developed from published studies, including patient satisfaction, surgical outcome and the 
standardized evaluation of photographs. 
The null hypothesis for the research objectives was that there was no difference in outcome between 
the FTA and suture groups: 
1.7.1 Objective I (Surgical outcomes and complications in the FTA and suture groups) 
• Were the eyelid measurements following blepharoptosis and blepharoplasty surgery different 
between the two groups? 
• Were the complication rates different between the two groups (e.g. amount of haemorrhage)? 
 
1.7.2 Objective II (Patient satisfaction in the FTA and suture groups) 
• Was patient satisfaction different between the two groups? 
• Was patient satisfaction different to surgical outcomes? 
 
1.7.3 Objective III (Photograph analysis in the FTA and suture groups) 
• Was there a difference in photograph scoring between the two groups? 
• Was there a difference of scoring between individual observers? 
 
1.7.4 Objective IV (Comparison between three outcome measures) 
• Were the outcome measures between surgical outcomes, patient satisfaction and photograph 
analysis different? 
• Are all of the measures required to define surgical outcomes? 
!
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1.8 Project Challenges 
High quality clinical research, including the use of randomized control studies that evaluate surgical 
techniques are rare in the field of oculoplastic surgery and a substantial number of challenges were 
encountered with the development of this project.  Although ptosis is a common condition there are 
multiple causes and potential confounding variables.  To reduce the number of confounding variables, 
inclusion and exclusion criteria were used to mitigate these variables. The implications for stringent 
trial criteria were to reduce patient numbers.  As a consequence the trial was multi-centred, with 
recruitment over two hospital sites, and the patient entry ran over a 3-year period.  FTAs are a 
relatively expensive technique at the time of conception of the study and Baxter (AG Industries, 
Austria) supplied the adhesives without any influence on study findings or conclusions.  A further 
challenge was developing the outcome measures for the study, diagnosis of ptosis and successful 
outcomes have been relatively ill-defined in the literature.  As part of the literature review the best 
evidence based medicine was used to further develop definitions and outcome measures.  The trial 
took almost 5-years from design to final analysis of results and conclusions. 
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2.0 Materials & Methods 
Randomized Control Study: A randomised control study was developed to evaluate surgical outcome 
following blepharoptosis correction or upper eyelid blepharoplasty, and skin closure with fibrin tissue 
adhesive compared to conventional sutures.  The trial underwent complete ethical approval (Appendix 
1) and complete pilot study before commencement.  Patients were entered into the trial over a 3-year 
period according to the trial protocol (inclusion and exclusion criteria) and to multiple centres in 
London (Charing Cross Hospital and Western Eye Hospital) from 2003-2006.   
Outcome measures: The literature was reviewed for methods of evaluation of skin closure and the 
grading of surgical outcome.  The definition of patient outcome was derived with three specific 
elements listed below.   
1.  Surgical outcome defined by measurements of eyelid position and complications e.g. haematoma, 
infection, further surgery.   
2.  Pre and post-operative measurements and photographs were taken at each out-patient appointment.  
The aesthetic appearance was evaluated by independent evaluation of standardized photographs by 
three independent consultants.  Published criteria were used for the grading of both facial appearance 
and quality of scar. 
3.  Patient satisfaction was evaluated by a published questionnaire of patient outcome. 
!
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2.1 Study Design 
2.1.1 Ethical approval 
 Ethical approval by Local Research Ethics Committee (LREC) was completed before the study was 
commenced (Appendix 1). 
2.1.2 Patient Selection 
There may be unpredictability with the results of ptosis surgery, with approximately 10% of 
procedures being complicated with over or under correction.  One of the limitations of previous 
studies has been the mixture diagnoses that have been evaluated in the same study (e.g. ptosis 
secondary to different aetiologies undergoing a range of a patient specific procedures including brow, 
upper and lower eyelid surgery).  Ageing of the upper lid often co-exists with aging of the brow, mid-
face and other facial changes. Additional procedures such as brow elevation, combinations of upper 
and eyelid procedures have been evaluated in previous studies with FTAs however does result in 
greater variability of the results. In this study there were defined inclusion and exclusion criteria to 
minimize the potential for confounding variables. 
Inclusion Criteria 
1. Patients requiring blepharoplasty procedure for involutional blepharoptosis or dermatochalasis 
2. Informed consent obtainable 
3. Patients available for follow-up 12 months after surgery 
 
Exclusion Criteria 
1. Previous eyelid surgery e.g. Tumour excision, ectropion, entropion, blepharoplasty 
2. Non-involutional aetiology of ptosis or dermatochalasis 
3. Complicated systemic conditions e.g. Thyroid eye disease 
4. Patients with only one functional eye 
5. Patients medically unfit for surgery or contraindications for FTA use e.g. pregnancy 
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2.1.3 Confounding factors 
Eyelid height following ptosis surgery is unexpectedly high or low in approximately 10% of ptosis 
corrections.  There a variety of potential confounding factors that influence the outcome following 
ptosis surgery and in this study steps were taken to mitigate these potential confounders.   
Although the surgical procedure was standardized there remain sources of variability within 
the study.  For example, the local anaesthesia contained a low concentration of adrenaline that was 
used to reduce intra-operative haemorrhage.  Although the volume of anaesthetic and adrenaline were 
standardized between cases (1:200 000), its effects may vary on individual patients, tissue 
concentration and the direct effect of the adrenaline on the sympathetically innervated Müller’s 
muscle that elevates the eyelid.  Although the effect of the adrenaline is thought to be relatively small, 
they may cause postoperative variability in eyelid height.   
 
Table 8 Confounding factors effecting postoperative eyelid height 
Confounding Factor Mitigation 
Involutional ptosis Exclusion of non-involutional ptosis 
Classification into mild, moderate and severe 
ptosis 
Systemic conditions Exclusion of systemic conditions known to effect 
eyelid height e.g. myaesthenia gravis 
Pre-existing Ocular conditions  Exclusion of ocular conditions and factors known 
to effect eyelid height e.g. previous ocular 
surgery, history of contact lens wear 
Intra-operative factors Standardized operation, supervision by a single 
consultant surgeon (JMO) 
Post-operative factors Standardized  post-operative procedures 
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Previous publications evaluating the use of FTAs on eyelid surgery have had considerable variability 
in diagnosis, surgical procedure and definition of surgical outcome.  The variability in these studies 
makes comparisons between FTAs and non-FTA skin closure difficult to evaluate.  There are very 
few RCTs that have evaluated the use of FTAs and no previous study has specifically evaluated skin 
closure following blepharoptosis or dermatochalasis. 
 
Table 9 Published Studies on FTA use in Eyelid Procedures 
Study Patient Selection Surgery Surgical Outcome 
(Mandel, 1990) Upper and lower eyelid 
blepharoplasty, 16 
patients 
Mixture; facial and 
other procedures 
Retrospective case 
series, recorded 
complications 
(Mandel, 1992) Upper and lower eyelid 
blepharoplasty, 32 
patients 
Mixture; facial and 
other procedures 
Retrospective case 
series, recorded 
complications 
(Mommaerts et al., 
1996) 
Heterogeneous mixture, 
mostly lower eyelid 
blepharoplasties, 18 
eyelids 
combined with brow 
and upper eyelid 
procedures 
Non-randomized 
compared with suture 
closure, photograph 
analysis of scar 
(Oliver et al., 2001) Not discussed, aesthetic 
indications, 20 patients 
Rhytidectomy RCT, Haemorrhage 
from drains only 
(Grossman et al., 2001) Mixture of facial 
aesthetic procedures, 105 
patients 
Mixture; forehead, 
eyelid, midface & 
neck 
Retrospective case 
series, recorded 
complications 
(Foster et al., 2006) No mention of diagnosis 
or aetiology of ptosis, 33 
patients 
Müller muscle-
conjunctiva resection 
Retrospective case 
series 
 
 
2.1.4 Randomization 
Patients that were diagnosed with involutional ptosis or dermatochalasis underwent preoperative 
assessment including evaluation against the checklist of inclusion and exclusion criteria.  
Randomization to the FTA or suture group was provided with sealed envelopes containing the 
treatment group, which were opened at the time of operative planning. Bilateral eyes were randomised 
as a singularity to as it was considered that a symmetrical procedure was ethical and the different 
surgical technique may result in an asymmetrical unsatisfactory outcome. Masking (blinding) with 
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respect to treatment was not possible following surgery because the distinctive attributes of treatment 
modalities. 
  
2.1.5 Sample Size Justification 
Sample size justification was completed using the most recently published FTA trial when the study 
was designed in 2002 (Table 9). No randomized control study has not been published that provided a 
measure of outcome in both FTA and no FTA groups. It was recognised that haemorrhage drained 
was not an ideal indicator of sample size as the level of haemorrhage in blepharoplasty surgery is 
generally very small, the measure provided the most objective measure available for the power 
calculation. 
 
 FTA No FTA 
Total haemorrhage drained/ mls    
Mean 10  30 
Standard deviation 21.16 37.74 
 
OLIVER et al. 2001. A prospective, randomized, double-blind trial of the use of fibrin sealant for face 
lifts. Plast Reconstr Surg, 108, 2101-5, discussion 2106-7 
 
Statistical calculation of patient numbers: 
Haemorrhage drained  mean  (sd) 
With use of FTA   10 (21.2) 
No FTA   30 (37.7) 
 
Using sample size formulae m= 2x[z(1-a/2)+ z(1-b)]2/ (delta)2 
Calculating values for a significance level of 5% ( z(1-a)2 = 1.96 ) and a power of 80%  
m= 2x [1.96+1.2816]2/ (sd)2 
m=24 
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2.2 Fibrin Tissue Adhesive Preparation 
The Tisseel FTA was available as a commercial kit and was prepared in accordance with the 
manufacturer’s instructions.  The Tisseel kit was stored between 2 to 8°C before use.  The product 
was prepared approximately 20minutes before use, with the components stored in four separate vials; 
2 vials of solvents and 2 vials of powders.  The Tisseel protein concentrate (containing human 
fibrinogen, plasminogen, plasma fibroectin, factor XIII) was reconstituted in the fibrinolysis inhibitor 
solution (bovine aprotinin).  The dried human thrombin was reconstituted in the calcium chloride 
solution. 
   
Table 10 FTA Constituents 
 Vials Components 
Constituent 1 
Protein concentrate 
 
Fibrinogen, Plasminogen, 
fibronectin, Factor XIII 
 Fibrinolysis inhibitor solution Aprotinin 
Constituent 2 
Dried protein Thrombin 
Solution Calcium chloride 
 
The Tisseel kit was prepared approximately twenty minutes before use.  The two components were 
preheated (10 minutes) before being mixed in a magnetic spinner on a heating plate (15minutes) and 
then inserted into a specialized “Duploject” syringe (Hyland Division, Baxter Laboratories 
Corporation) (Figure 6).  The syringe mixed the components at its tip for application to the two 
wound surfaces.  Once mixed the sealant takes only one minute to activate and three minutes to 
solidify.  The adhesive is only prepared immediately prior to use, and the skin tissues fully prepared 
before application of the FTA (Giampapa and Bitar, 2002).  The thrombin comes in two 
concentrations (500IU and 41IU/ml) these result in a fast and slow setting solution respectively.  The 
fast setting solution was used for skin closure and previous reports of the slow setting mixture have 
suggested it is unreliable for skin approximation (Mommaerts et al., 1996).   
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Figure 6 FTA Preparation 
 
 
 
Upper:  Preheating of constituents, Centre: Reconstitution of aprotinin, Lower: Insertion of syringe 
into Duploject 
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2.3 Surgical Procedure 
 2.3.1 Blepharoptosis surgery 
The blepharoptosis was performed by a senior oculoplastic fellow under the supervision of a single 
consultant (JMO) by a previously reported technique (Anderson and Dixon, 1979b, Anderson and 
Dixon, 1979a, Mandel, 1990, Mandel, 1992, Linberg et al., 1988).  All the procedures were performed 
under local anaesthesia with sedation as this enabled lid height, contour and symmetry to be adjusted 
using patient cooperation during the operation.  The local anaesthesia use was combination of 
lidocaine 1% and bupivocaine 0.25% with 1:200 000 adrenaline. The bupivocaine has a longer half-
life and provides postoperative analgesia. The low concentration adrenaline reduced local 
haemorrhage and aids in prolonging the effect of the local anaesthesia. A small volume of local 
anaesthesia (<1 ml) was injected subcutaneously, care was taken to ensure the anaesthesia was not 
injected deeply through the orbital septum as it may alter the levator superioris and Müller’s muscle 
action.  In the past, patients had surgery under general anaesthesia with a predefined “cookie-cutter” 
surgical technique that had limited results.  To increase the postoperative predictability and 
consistency local anaesthesia was adopted as it enabled voluntary involvement of the patient to adjust 
lid height intraoperatively. 
The surgical technique has been previous described by Anderson and Dixon (Anderson and 
Dixon, 1979b, Anderson and Dixon, 1979a), a summary is described below: Preoperative marking of 
the skin crease and excess skin was conducted with the patient in the supine position.  A skin crease 
incision was made and the excess skin and underlying orbicularis muscle excised as a single crescent 
shaped flap (Figure 6).  The orbicularis was then tented upwards and a full thickness incision made 
through the orbicularis to the anterior tarsal surface with the scissors perpendicular to the tissues.  The 
orbicularis incision was then completed with a minimal number of cuts to reduce unnecessary 
haemorrhage from multiple incisions.  Blunt dissection with a cotton bud was used to identify the 
orbital septum and levator aponeurosis.  The orbital septum was opened and to aid identification of 
the levator aponeurosis the patient was asked to look up and down which corresponded to movement 
of the aponeurosis.  If the fat pads were found to have prolapsed on preoperative examination they 
were identified, freed and excised with meticulous attention to haemostasis.  The aponeurosis edge 
and posterior surface was released and the aponeurosis was reattached to the mid-tarsus with three 6/0 
absorbable mattress sutures (Vicryl, polyglactin 910) (Figure 7).  With each suture the eyelid was 
everted to ensure partial thickness tarsal bites to avoid secondary corneal erosions.  The first central 
suture was placed just medial to the mid-pupillary line (highest point of eyelid) and two subsequent 
sutures medial and lateral to the first (Figure 8).  The eyelid height and contour were checked with the 
patient looking in up and downgaze before the sutures were tied off, with the aim of 1mm 
overcorrection as there is usually a small drop of 1mm eyelid height in the postoperative period as a 
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consequence of the adrenaline and local anaesthetic effects having worn off.  If the eyelid height was 
too high or too low, or the eyelid contour unsatisfactory, the suture positions on the levator or tarsus 
were adjusted accordingly.  The skin crease was internally reformed using three 6/0 interrupted 
sutures (Vicryl) from the edge of the levator aponeurosis then through the lower orbicularis but not 
through the epidermis.  The skin was then closed in accordance with its preoperative randomization to 
the FTA or suture groups. 
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Figure 7 Skin Crease Incision & Crescent Shaped Blepharoplasty 
 
Figure 8 Aponeurosis Edge & Posterior Surface Release 
!
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Figure 9 First Central Suture Just Medial to the Mid-Pupillary Line 
 
 
Acknowledgement for Figures 7-9 from McCord: (McCord et al., 2007) 
 
!
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2.3.2 Blepharoplasty surgery 
The patients underwent preoperative marking of the excess upper eyelid skin and fat pad prolapse 
with the patient in the supine position, conservative excision was planned to ensure adequate closure 
of the eyelids post-operatively with a minimum residual measurement of 20mm from brow to upper 
lid margin.  Local anaesthesia was applied subcutaneously under sedation in an identical manner to 
the blepharoptosis surgery.  The surgical technique used was a relatively standard technique that has 
been summarized below (Fagien, 2002, Rohrich et al., 2004, Siegel, 1992). Skin excision was 
completed, followed by excision of a thin strip of orbicularis muscle.  In patients where fat prolapse 
had been preoperatively identified and marked, the orbital septum was opened and fat excision 
completed with meticulous care to maintain haemostasis of the adipose tissue.   
In the suture group, the skin was closed with 7/0 interrupted absorbable sutures (Vicryl) or 
continuous 6/0 non-absorbable suture (Ethilon) along the length of the incision.  The wound was 
covered with a paraffin gauze dressing (Jelonet, Smith & Nephew) and bandaged for one hour.   
 
Figure 10 Blepharoplasty Preoperative Marking 
 
Acknowledgement for Figure, modified from (Rohrich et al., 2004) 
  
!
!
62!
2.3.3 FTA Application 
In the FTA group, the adhesive (Tisseel: Baxter AG, Vienna, Austria) was reconstituted in accordance 
with the manufacturer’s instructions approximately twenty minutes before use.  The two constituents 
were inserted into a Y-shaped delivery system that ensured equal volume mixing of the two 
components immediately prior to application. 
Meticulous attention was taken to ensure an absence of active haemorrhage and wound 
tension.  The FTA was applied to the skin edges with apposition of the everted skin edges with two 
pairs of forceps for two minutes (Figure 10).  The wound was checked for gapes and where necessary 
further FTA applied.  The excess FTA was not wiped off and no dressing or antibiotic ointment was 
applied.  A Cartella eye shield was used to protect the skin at night for the first week. 
 
Figure 11 Intra-Operative FTA Application 
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Figure 12 Post-FTA Application 
 
 
 
2.3.4 Postoperative Management 
Hypromellose (0.3%) and chloramphenicol (0.5%) drops were applied four times a day and 
chloramphenicol ointment (1%) once at night for a two-week period.  Patients were advised to sleep 
with the head of the bed elevated with 2-3 pillows and to commence cold compresses 24 hours after 
surgery, applying the compress for 10-15 minutes, approximately 8x day for one week.  
All patients attended postoperative outpatient appointments at 1 week, 3 weeks and 4 months.  
At each appointment assessment included visual acuity, intraocular pressure, lid measurements and 
standardized digital photographs.  
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2.4 Outcome Measures 
2.4.1 Surgical Outcomes  
The development of objective outcome measures for surgical procedures can be challenging to define.  
There are often multiple different parameters that can be measured some with greater objectivity (e.g.  
eyelid measurement) and some equally important  yet less well defined criteria (e.g. asymmetry).  The 
definitions can be controversial and developing outcomes that can be utilized in widespread clinical 
practise, such as PROMs, are not straightforward.   
 Surgical results from ptosis correction are commonly described in absolute proportions of 
success or failure. Closer evaluation of the definition of success however does identify different 
definitions of success, for example within 1mm of the desired height at 7-years is completely different 
to <0.5mm inter-lid difference at 3-months (Table 11). In addition there are multiple confounding 
factors that may influence outcomes, including the grouping of different aetiologies of ptosis and both 
surgical technique and experience. The large variations in success rates from 74% to 95% are a 
reflection of the considerable variability in study criteria.   
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Table 11 Publications of Involutional Ptosis Success Rates 
Authors 
Diagnosis, Surgery, 
Follow-Up period 
No. of 
Eyelids 
Definition of Success Success 
(Older, 1983) Acquired ptosis, 6-
months to 7-years 
113 <1mm of desired height 95%  
(Collin, 1986) Involutional ptosis, 
anterior or posterior 
approach, up to 8-
years 
105 Absence of redo surgery 87% 
(Berlin and Vestal, 
1989) 
Involutional ptosis, 6-
weeks 
174 Margin reflex distance 2-
4mm 
74%  
(Shore et al., 1990) Blepharoptosis, levator 
resection 
157 Unsatisfactory results 
Absence of redo surgery 
82% 
88% 
(Liu, 1993) Levator function 
>8mm, single stitch, 
1.5 to 8 years 
169 Absence of redo surgery 
<1mm of desired height 
93% 
95%  
(Tucker and 
Verhulst, 1999) 
Involutional ptosis, 
anterior approach, 2 to 
24-months 
164 Absence of redo surgery 
<1mm of desired height 
82% 
95%  
(Meltzer et al., 
2001) 
Single stitch, anterior 
approach, 3-months 
 <0.5mm inter-lid difference 90%  
(McCulley et al., 
2003) 
Acquired ptosis, 6-
weeks to 1-year 
828 Absence of redo surgery 
Within desired range 
91% 
77% 
(Frueh et al., 2004b) Involutional ptosis, 
single stitch,  
49 Absence of redo surgery, 
<0.5mm inter-lid difference, 
& 2-4 marginal reflex 
distance 
98% 
75% 
67%  
(Scoppettuolo et al., 
2008) 
Involutional ptosis, 
UK audit 
223 1.Margin reflex distance 3-5mm 
2.Interlid difference  ≤1mm 
3.Interlid crease ≤2mm 
4.Symmetrical contour 
5.Absence of redo surgery 
74% 
87% 
N/A 
N/A 
97% 
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The outcomes used in this study were developed from the best evidence-based medicine (EBM) on 
surgical outcomes following blepharoptosis surgery.  One of the landmark papers in the UK, was a 
national audit on ptosis surgery, that defined a number of surgical outcomes for ptosis surgery 
(Scoppettuolo et al., 2008).  These outcome measures were developed by the British Oculoplastic 
Surgery Society (BOPSS) following consultant discussion (Scoppettuolo et al., 2008).  These outcome 
measures developed by BOPSS focused on marginal reflex distance, this excluded errors induced by 
measurements of the lower eyelid position, which may itself be affected by confounding factors 
unrelated to the ptosis such as laxity or retraction.  Ptosis was defined as drooping of the upper eyelid 
with a reduced marginal reflex distance of ≤2mm.  Other measurements of the eyelid that have been 
used to describe successful outcome include interlid difference, lid show and skin crease and are 
shown in the table below. 
 
Table 12 Definition of Successful Surgical Outcome 
 Outcome Measure Definition of Success 
1 Margin reflex distance    3-5mm 
2 Interlid marginal reflex difference  ≤1mm 
3 Interlid crease difference   ≤2mm 
4 Interlid show difference    ≤2mm 
5 Symmetrical lid contour   Yes 
6 Redo surgery No 
 Complete success All criteria met 
 Partial success  One or more of the 
measurements was outside the 
defined range 
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Complications 
The complications of ptosis can be classified anatomically into those affecting the skin relating to the 
skin, complications of the periocular tissues, generalized complications and very rare vision 
threatening complications.  
Complications that are related to skin closure include the development of localized 
inflammation and granuloma formation, which may require conservative management with anti-
inflammatory ointment or surgical intervention. Dehiscence of the wound may require surgical 
intervention and closure of the skin. Complications relating to the transcutaneous skin incision include 
scarring and absent crease, these maybe related to both the method of skin closure and the surgical 
technique. Seroma and necrosis are both very rare complications of eyelid surgery, however they have 
reported in patients who have undergone surgery with skin closure with the use of FTAs (Putterman 
and Urist, 1976, Smith and Nesi, 1979). 
Complications relating to the eyelid height include overcorrection, undercorrection and 
unsatisfactory contour or asymmetry.  Undercorrection, the most common complication relating to lid 
height may result from inadequate resection or elevation of the levator, failure to identify the 
anatomical structures, excessive scarring or misplaced sutures, and occurs in 10-15% of cases. 
Overcorrection results increased lagophthalmos, dry eye syndrome and keratopathy, preoperative 
assessment for dry eye and cautious patient selection are important to prevent this complication, 
lagophthalmos is common immediately after upper eyelid blepharoplasty and usually resolves (Lelli 
and Lisman).  Hypertrophic scarring has been reported more in oriental and Afro-Caribbean patients, 
however no cases of keloid have been described following eyelid surgery (Lowry and Bartley, 1994).  
Permanent visual loss is very rare after upper eyelid blepharoplasty, however may occur as a 
result of retrobulbar haemorrhage, globe perforation, ischaemic optic neuropathy and others (DeMere 
et al., 1974, Hass et al., 2004).  Retrobulbar haemorrhage is the most common of the permanent visual 
loss with an approximate risk of one in 10, 000. Retrospectively there are often predisposing factors 
including hypertension, vascular disease and anticoagulation, however these factors are common in 
patients with involutional blepharoptosis (Lelli and Lisman, 2010).   
Common generalized complications that occur in the majority of patients include some 
ecchymosis (bruising) of the tissues and swelling. The presence of severe swelling or bruising maybe 
pathological and indicate a more serious complication e.g. haematoma. Infections of the eyelids 
following surgery are uncommon complications, topical antibiotics are used routinely to reduce this 
risk. Elevation of the eyelid, often results in lagophthalmos and increased dry eye symptoms, these 
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usually settle over a period of weeks, however in some patients dry eye and exposure keratopathy may 
cause long-term symptoms. 
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Table 13 Complications of ptosis and blepharoplasty surgery 
Classification Complication References  
Low Morbidity   
Acute 
Inflammation (Grossman et al., 2001, Gausas, 
1999, Lowry and Bartley, 1994, 
Morax and Touitou, 2006, 
Murakami and Plant, 1994) 
DeMere et al., 1974) 
Granuloma 
Infection 
Dehiscence 
Haematoma 
Inclusion cysts, milia (Adams and Feurstein, 1986) 
Hypersensitivity, allergy, urticaria, 
pruritus* 
(Lee et al., 2009) 
Medium-Long Term 
Undercorrection/ Overcorrection (Collin and Tyers, 1985) (Collin, 
1979, Beard, 1972, Rycroft, 
1967, Tucker and Cabral, 2000) 
Asymmetry/ Absent skin crease/ 
Hypertrophic (prominent skin 
crease) 
Dry Eye Syndrome & 
Lagophthalmos 
Diplopia  (Syniuta et al., 2003) 
Lacrimal Gland Prolapse (Smith and Lisman, 1983) 
Periocular pigmentation (Adams and Feurstein, 1986, 
Putterman, 1983) 
High Morbidity   
Localized 
Necrosis (Putterman and Urist, 1976, 
Smith and Nesi, 1979) 
Generalized 
Anaphylaxis (Lee et al., 2009, Radosevich et 
al., 1997) 
Permanent Visual Loss 
(0.0045% = 1 in 10 000) 
Retrobulbar Haemorrhage (DeMere et al., 1974, Hass et al., 
2004) 
Globe perforation (Darlington et al., 2006) 
Ischaemic optic neuropathy (Kordic et al., 2005) 
Other: e.g. Angle closure glaucoma (DeMere et al., 1974, Wride and 
Sanders, 2004, Moser et al., 
1973) 
* Hypersensitivity, allergic and anaphylactic reactions, although no adverse events of this type were 
reported during clinical trials  
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2.4.2 Photograph Analysis 
 Historically the evaluation of surgical results was focused on surgical outcomes that could be 
measured such as eyelid height or palpebral aperture, complications that could be identified by 
retrospective records or by straightforward observation of symmetry.  The subjective evaluation of 
symmetry and aesthetic result is fraught with bias and provides poor quality of evidence based 
medicine (Parsa et al., 1998, Most et al., 2002).  The use of standardized photographs that are 
evaluated by masked observers is a more objective evaluation of outcomes.  The use of three 
observers and repetition on more than one occasion enables statistical analysis to evaluate the inter-
test and intra-test reliability.  This was the adopted methodology for this study to measure surgical 
outcome.   
Photographs were taken of each patient at each post-operative appointment 1-week, 3-weeks 
and 4-months.  All photographs were taken in standardized positions: primary gaze, upgaze, 
downgaze and high magnification of the surgical wound.  The photographs were collated and 
randomly allocated to a PowerPoint slide (Microsoft Office, 2007).   The masked photographs were 
then graded by three senior ophthalmic specialists who were not directly involved in the study other 
than to assess the outcomes.  The reviewers were unaware of the treatments used in the study, 
assignment to suture or FTA group, time point of assessment or the identity of the patient or operating 
surgeon.  The scoring was repeated one month later on a second occasion with the identical 
photographs presented in a different order. 
The data obtained was analyzed using Spearman’s rank correlation coefficient for intra- and 
inter-observer reliability (in addition to Bland Altman plot).  To provide an overall assessment of the 
scar the two scores of each of the three examiners were averaged.  The method of analysis was similar 
to that used by Mommaerts et al to compare the results of a heterogeneous group of patients that 
underwent photograph analysis of eyelid surgery (Mommaerts et al., 1996).  A modified scoring 
system was developed based on the publications of both ptosis and scar evaluation.  The scoring 
included the overall appearance and symmetry of the eyelids and a more detailed analysis of the scar 
shown in the table below.   
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Table 14 Photograph Evaluation of Outcome 
Scoring  Normal Suboptimal 
Ptosis Evaluation 
(Frueh et al., 2004a, 
Carter et al., 2001, 
Feibel et al., 1993) 
Superior lid crease 
Eyelid contour 
Superior sulcus 
Compared to pre-op 
Step-off border (borders not in same plane) 
0 
0 
0 
0 
0 
1 
1 
1 
1 
1 
Scar Evaluation (1-4) 
(Hollander et al., 1995, 
Mommaerts et al., 
1996, Toriumi et al., 
1998, Greene et al., 
1999) 
Contour irregularity (wrinkled skin near wound) 
Margin separation (gap between sides)  
Edge inversion (wound not everted) 
Excessive inflammation (swelling, oedema) 
Overall cosmetic appearance 
0 
0 
0 
0 
0 
1 
1 
1 
1 
1 
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2.4.3 Patient Experience 
The World Health Organization defines health as the state of “complete physical, mental and social 
well-being”.  Historically healthcare have been physician-centred and outcome measures focused 
around physical outcomes, surgical complications and procedure related measurements (Laine and 
Davidoff, 1996).  There is an increased requirement to place patient’s well-being at the centre of 
healthcare provision and ensure a patient-centred service.  A combination of social changes with 
increased consumerism, media and access to information through the internet has fuelled increased 
levels of patient education and expectation (Neuberger, 2000).  The measurement of patient 
experience and PROMs following facial surgery has importance for both functional and cosmetic 
procedures.  Increasing importance has been placed on demonstrating the benefits of eyelid surgery to 
patients, to justify surgical intervention and demonstrate that surgery is both of low risk and high 
quality (Darzi, 2007).   
There are few studies that have evaluated outcomes from facial surgery and none for eyelid 
procedures from the patient’s perspectives.  The patient’s perspective is of critical importance in 
determining success and the primary determinant of patient satisfaction, yet measures of patient 
experience have been poorly developed (Ford et al., 1997, Linder-Pelz, 1982).   There is evidence that 
greater patient satisfaction is associated with increased patient compliance with medical 
recommendations, reduced malpractice suits and increased profitability (Neuberger, 2000, Sherbourne 
et al., 1992, O'Brien et al., 1992, Hart et al., 1990, Hickson et al., 2002, Levinson et al., 1997).  
Although patient experience in its simplest form may involve straightforward questions, caution must 
be taken in interpreting simplistic measures as they are often inaccurate and subject to bias (Parsa et 
al., 1998).  The medical literature is fraught with studies proposing a vague notion of patient 
experience (Alsarraf, 2002).   For example, a surgeon verbally asking a patient in their clinic 
regarding the outcomes is likely to produce biased results as patients may not feel comfortable in 
answering such questions if they are negative and with implications to their future care, yet in the past 
this would have not been atypical.  Therefore to measure patient experience requires adequate 
resources to support the development of validated questionnaires with a team of skilled researchers 
and surgeons.  Effective and accurate questionnaires must be tested for validity, reliability and 
sensitivity to measure change.   
The data collection may include a wide spectrum of assessment tools that collect information 
from either written or oral means, show in Table 16.  The form of data collection includes three 
principal areas of measure.  Firstly “procedural satisfaction” which is the most commonly measured 
outcome including satisfaction with the procedure itself, recovery period, side effects and 
complications.  Without attention to methodology, bias that favours a more positive experience may 
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be introduced, for example a surgeon asking patient for satisfaction in the clinic.  Secondly, 
“functional and symptom improvement” for example in blepharoptosis surgery symptoms measured 
prior to surgery could include reduced field of vision, reduced vision, difficulty with lifestyle 
measures such as driving.  Post-surgery the same measures are reassessed.  Thirdly “psychological 
functions” that includes self-perception, self-concept and psychological functions.  Self-perception of 
facial appearance includes willingness of patient to change their appearance and to have additional 
procedures.  Self-concept includes aspects of self-esteem, confidence, negative feelings on oneself 
and embarrassment of appearance.  Psychological functions include anxiety, depression, avoidance of 
social situations and ability to enjoy life. 
Despite a need for quantitative assessment of quality of life measures there is a relative 
paucity of research activity defining such outcome measures for facial procedures.  Kosowski 
conducted a literature review to identify PROMs that has been developed to evaluate facial surgery 
outcomes (Kosowski et al., 2009).  Only nine tools were identified that presented “true” PROMs and 
each had some limitations with respect to its data collection, data measures or validation.  This review 
highlighted the challenges in developing accurate and effective PROMs and the need for specialized 
personnel and adequate resources for the development of useful outcome measures.   
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Table 15 Patient Reported Outcome Measures (PROMs) 
Method Tools 
Data Collection 
Written: Analogue scores 
Written: Validated questionnaire 
Oral: Structured interviews 
Oral: Patient groups 
Oral: Expert opinion 
  
Data measures 
Procedural satisfaction 
Functional/ symptoms 
Psychological functions (Psychological well-being, Self-
perception, self-concept) 
  
Test Validation 
Reliability (inter-person, intra-person) 
Validity (compared to other measures) 
Responsiveness (sensitivity of measure) 
Acceptability 
Confounding factors/ Errors (e.g.  missing data) 
Modified from: (Kosowski et al., 2009) 
 
The field of ophthalmology and the sub-specialty oculoplastics has limited research on patient 
expectations with the exception of outcomes following cataract surgery (Dawn and Lee, 2004, Tielsch 
et al., 1995).  Although the subject of patient expectations has received increased attention and 
research in recent years the majority of research has been in the primary care setting and may have 
limited accuracy in the evaluation of surgical procedures.   
 A variety of measures of patient experience have been developed each with both advantages 
and limitations.  The commonest limitations of patient experience tools were highlighted by Isenberg 
and Rosenfeld (Isenberg and Rosenfeld, 1997).  The principal limitations included a lack of resources 
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for data collection, analysis and interpretations, inadequate communication between the tool 
researchers and the clinicians, and overly complex and long questionnaires that are limited in their 
practical application. 
In this study we adopted a patient experience questionnaire that had previously been utilized, 
shown in Appendix 8 (Alsarraf, 2000, Alsarraf, 2002, Alsarraf et al., 2001).  The questionnaire had 
previously been validated with excellent test-retest reliability and internal consistency (reliability 
coefficient P<0.001) (Alsarraf et al., 2001, Jaggi et al., 2009).  In addition the test was straightforward 
to perform and took only a few minutes to complete.  Each response was scored from 0 to 4, with the 
most negative response scoring a 0 and the most positive response scoring 4.  The total of six 
questions resulted in a score between 0 to 24, the score was then converted to a percentage to give a 
scaled instrument score.   
! 76!
Table 16 Blepharoptosis Outcomes Evaluation and Data Measure 
Data Measure Questions/ Each question scored from  
0 (Not at All) to 4 (Completely) 
Procedural satisfaction 
How well do you like the appearance of your eyes? 
Would you like to surgically alter the appearance 
of your eyes? 
  
Functional/ symptoms 
Do you feel like the appearance of your eyes 
makes you look tired? 
How much do you feel your friends and loved ones 
like the appearance of your eyes? 
  
Psychological functions (Psychological well-
being, Self-perception, self-concept) 
Do you feel the current appearance of your eyes 
limits your social and professional activities? 
How confident are you the appearance of your eyes 
is the best that it can be? 
 
 
2.5 Data Collection & Analysis 
2.5.1 Data Collection 
Each patient was examined in the postoperative period at 1-week, 3-weeks and 6-months.  At each 
appointment the patient underwent a comprehensive assessment based on a preoperative standardized 
form show in Appendix 6. 
The assessment included closed questioning on symptoms, including irritation, watering and 
discomfort.  Standardized measurements of the eyelids included marginal reflex distance, palpebral 
aperture, skin crease, lagophthalmos and slit-lamp biomicroscopy with examination of the cornea.   
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2.5.2 Statistical Analysis  
The data from the two groups were compared with t-testing and Chi-square testing.  Photograph 
analysis scores were evaluated with Mann-Whitney test, an α-risk of 0.05 was accepted as clinically 
significant and the analysis completed using Microsoft Office Excel® 2007.   
The photograph scores were evaluated for test reliability and internal consistency.  Pearson’s 
correlation coefficients were used to evaluate the test reliability and consistency.   
In this study both unilateral and bilateral eyelids were treated as a singularity for the purpose of the 
study. This represented a compromise as measurements such as the marginal reflex distance were 
considered independent variables that would not be the case in bilateral eyelids. For measurements 
dependent on a comparison with the second eyelid such as the interlid difference, these 
measurements were excluded for bilateral cases. 
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3.0 Blepharoptosis Results 
Fifty-one patients were entered into the blepharoptosis trial between 2003 and 2006.  Three patients 
declined entry into the trial and seven patients were excluded for associated co-morbidity.  Of the 51 
patients (27 men; 45%), the average age was 67 years (median 70 years; range 41-88 years), Twenty-
three (45%) of the patients were male and thirty-six cases (71%) were unilateral.  Of the 51 patients 
38 (75%) were Caucasian, 10 (20%) were Afro-Caribbean and 3 (5%) were Asian.   
3.1 Patient Demographics 
Following diagnosis of involutional blepharoptosis patients were randomized to the FTA and suture 
group for skin closure.  A summary of the demographic information for the two groups is show in the 
table below.  The ages (t=0.27; p=0.79), proportions of unilateral cases, race and follow-up period 
were similar in the two groups (p>0.05).   
Table 17 Demographic Information for Blepharoptosis Patients 
 FTA group Suture group 
Number of Patients 27/51 (53%) 24/51 (47%) 
Age 
   Mean 
   Median 
   Range 
 
67 
72 
41-88 
 
66 
69 
48-86 
Proportion of Males 12/27 (44%) 15/24 (46%) 
 Proportion of Unilaterals 19/27 (70%) 17/24 (71%) 
Race 
   Caucasian 
   Afro-Caribbean 
   Asian 
 
19/27 (70%) 
6/27 (22%) 
2/27 (7%) 
 
19/27 (79%) 
4/27 (17%) 
1/27 (4%) 
Follow-up Period (months) 
   Mean 
   Median 
   Range 
 
11 
11 
10-17 
 
13 
15 
11-19 
Blepharoptosis surgery 
included blepharoplasty 
12/27 (44%) 12/24 (50%) 
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3.2 Surgical Outcomes 
The surgical outcome measures are summarized in Table 18 and 19 below.  The FTA group had a 
mean preoperative MRD of 0.9 mm (range -3.0 to 3.0 mm, SD 1.0), difference to contralateral eyelid 
of 2.7 mm (range 1.0 to 8.0 mm, SD 1.5) and levator function of 13 mm (range 10-18 mm, SD 2.7).  
There was no statistical difference with the suture group, MRD (t=0.34, p=0.73) (Table 2).   
 In the suture group the outcomes were statistically better in the FTA group for the inter-MRD 
≤1mm (suture group 0.4 ±0.6mm, FTA group 0.8 ±0.7mm, t-test = 2.2126, p= 0.043).  The MRD 
distance (Success: 3-5mm) was higher in the FTA group (3.3 ±1.4mm) compared to the suture group 
(suture group 3.0 ±1.3mm), however not of statistical significance.  
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Table 18 Surgical Pre-Operative and Post-Operative (6-months) Measurements for 
Blepharoptosis Patients 
  FTA Group Suture Group Statistic Test 
(t-test) 
Pre-
operative 
Margin Reflex Distance 
(mm) 
0.9 (1.0) 1.0 (1.2) 
t = -0.34, 
p=0.732 
Mild (≥1.5mm) 7 (20%) 9 (29%)  
Moderate (0.5-1.0mm) 18 (51%) 12 (39%)  
Severe (≤0mm) 10 (29%) 10 (32%)  
 Difference to 
contralateral eyelid 
(mm) 
2.7 (1.5) 2.7 (2.4) 
t = -0.032, 
p=0.975 
Levator function (mm) 
13.3 (2.7) 13.5 (1.8) 
t = -0.33, 
p=0.744 
Post-
operative 
(6-months) 
Margin Reflex Distance 
(mm)  
3.3 (1.4) 3.0 (1.3) 
t = 0.943, 
p=0.349 
Difference to 
contralateral eyelid 
(mm) * 
0.8 (0.7) 0.4 (0.6) 
t = -2.126, 
p=0.043** 
*excluding bilateral cases, **p < 0.05, ( ) = Standard deviation 
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The measurements were evaluated by the UK National audit definition of complete and successful 
outcome of ptosis surgery (Scoppettuolo et al., 2008). Although not statistically significant, the 
proportion of successful and partially successful operations were higher in the suture closure group.  
The outcome measure results are show in the table 19 below. 
 
Table 19 Successful Outcomes for Blepharoptosis surgery 
 Successful Outcome Measure FTA Group Suture Group Statistic Test 
(Chi-Squared) 
1 Margin reflex distance ( 3-5mm) 69% (24/35) 81% (25/31) χ = 0.263, 
P>0.05 
2 Interlid marginal reflex difference 
(≤1mm)* 
82% (22/27) 96% (23/24) χ = 0.112, 
P>0.05 
3 Redo surgery (No) 94% (33/35) 97% (30/31)  - 
 Complete success (All criteria met) 63% (22/35) 77% (24/31) χ = 0.199, 
P>0.05 
 Partial success (One or more of the 
measurements was outside the 
defined range) 
91% (32/35) 97% (30/31) χ = 0.234, 
P>0.05 
* Bilateral cases counted only once, Postoperative outcomes in FTA and suture closure groups from 
UK national ptosis audit (Scoppettuolo et al., 2008)). 
 
Overall there were similar proportions of short-term complications between the two groups. Although 
the levels of post-operative (Weeks 1-3) irritation were double in the suture closure group (FTA 
group n=3, Suture group n=6), the numbers were not of statistical significance.  One patient in the 
suture group had a post-operative suture granuloma that was managed conservatively.  
There were no intra-operative complications that occurred as a consequence of the FTA or sutures, 
and no cases required a change in management as a result of FTA randomization.  The surgical 
outcome measures are summarized in the table below.  
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Table 20 Symptoms following Blepharoptosis Surgery: 1-3 Weeks 
 Symptoms FTA Group Suture Group 
 
Discomfort/ Pain 1 1 
Pruritus/ Irritation 3 6 
Other (Watering, Discharge) 3 3 
Total  20% (7/35) 32% (10/31) 
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Table 21 Complications following Blepharoptosis Surgery: 1-3 Weeks 
 Complication FTA Group Suture Group 
Low 
Morbidity 
Inflammation/ Swelling 2 2 
Granuloma 0 1 
Infection 0 0 
Dehiscence 0 0 
Ecchymosis/ Haematoma 2 2 
Absent skin crease 0 0 
Prominent skin crease/ Asymmetry 1 0 
Exposure keratopathy 3 3 
    
High 
Morbidity 
Necrosis 0 0 
Anaphylaxis 0 0 
Retrobulbar haemorrhage 0 0 
Globe perforation 0 0 
Ischaemic optic neuropathy 0 0 
    
Total Complications 23% (8/35)* 26% (8/31)* 
* χ = 0.218, P>0.05 
 
Four months post-surgery there was mild asymmetry in one eyelid in the suture group and four 
eyelids in the FTA group.  Three patients were subsequently excluded from the study with inadequate 
follow-up.  In both groups there was no evidence of wound dehiscence, allergic reaction or infection.  
In addition to the three cases of redo ptosis surgery, one patient in the suture group required 
subsequent upper lid blepharoplasty.  There was one case of dry eye syndrome in both groups that 
was managed conservatively with long-term tear lubricant drops and ointment. 
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Table 22 Symptoms following Blepharoptosis Surgery: 4 months 
 Symptoms FTA Group Suture Group 
 
Discomfort/ Pain 0 0 
Pruritus/ Irritation 1 1 
Other (Watering, Discharge) 1 1 
Total  6% (2/35) 6% (2/31) 
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Table 23 Complications following Blepharoptosis Surgery: 4 months 
 Complication FTA Group Suture Group 
Low 
Morbidity 
Inflammation 0 0 
Granuloma 0 0 
Infection 0 0 
Dehiscence 0 0 
Absent skin crease 0 0 
Scarring (including prominent skin 
crease) 
0 0 
Exposure Keratopathy 1 1 
    
High 
Morbidity 
Necrosis/ severe scarring 0 0 
Reduced visual acuity 0 0 
Systemic infection 0 0 
    
Total Complications 3% (1/35) 3% (1/31) 
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3.3 Photographic Outcomes 
An example of the pre and postoperative photographs are show in the subsequent figures.  
Figures 13 and 14 shows a right side blepharoptosis in primary gaze and down gaze.   
Figures 15 and 16 shows the same patient in the 3rd postoperative week following FTA skin closure, 
the right eyelid has been corrected and the patient has a good symmetrical appearance. 
Outcomes for the photography analysis were significantly worse for ptosis evaluation in the FTA 
group (Score=2.7) compared to the suture group (Score 0.6, Mann-Whitney test P= 0.0029).  The 
outcomes for the scar evaluation were similar in the FTA group (Score=1.8) and FTA group 
(Score=1.4) (P>0.05).  The surgical outcome measures are summarized in the table 22 below. 
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Figure 13 Ptosis Pre-Operative Photograph in Primary Gaze 
 
 
 
Figure 14 Ptosis Pre-Operative Photograph in Down Gaze 
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Figure 15 Ptosis Post-Operative Photograph Week 3 in Primary Gaze 
!
 
 
Figure 16 Ptosis Post-Operative Photograph Week 3 in Down Gaze 
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Table 24 Photographic Outcomes for Blepharoptosis at 6-months Post-Surgery 
  
FTA Group 
Score 
Suture Group 
Score 
Statistic 
Test  
(Mann-
Whitney) 
Ptosis 
Evaluation 
Superior lid crease 
Eyelid contour 
Superior sulcus 
Compared to pre-op 
Step-off border (borders not in same 
plane) 
2.7 (2.2) 0.6 (0.8) 
MW = 42.5 
P = 0.0029* 
Scar 
Evaluation 
Contour irregularity (wrinkled skin 
near wound) 
Margin separation (gap between sides)  
Edge inversion (wound not everted) 
Excessive inflammation (swelling, 
oedema) 
Overall cosmetic appearance 
1.8 (1.3) 1.4 (1.1) 
MW = 90.0 
P = 0.3397 
Total Score 
 
4.4 (3.1) 2.1 (1.8) 
MW = 75.5 
P = 0.0471* 
* = p < 0.05, Score 0 (Normal) -> 10 (Maximal suboptimal), ( ) = Standard deviation 
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The three observers evaluated the standard photographs on two separate occasions and the results 
were evaluated using Spearman’s rank correlation coefficient for intra- and inter-examiner reliability. 
The results are summarized in the table below, the intra-examiner scores ranged from 0.47 to 0.61 
with a probability of <0.05. 
 
Table 25 Intra-Examiner Correlations between the Photograph Scores 
 Observer Correlation Probability 
Total Score 
Observer 1 
Observer 2 
Observer 3 
0.47 
0.61 
0.51  
0.0081 
0.0003 
0.0041 
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3.4 Patient Satisfaction Outcomes 
Patient satisfaction as evaluated by the validated questionnaire was similar in the two groups (FTA 
group score=18.6 and suture group score=17.4). The majority of patients were satisfied in both 
treatment groups, although it was noted that individuals who had lower level of satisfaction were not 
necessarily the patient who had a poorer outcome on objective assessment of eyelid measurements or 
photograph scores.  
 
Table 26 Patient Satisfaction Outcomes for Blepharoptosis Surgery 
Questions / Each question scored from: 
    0 (Not at All) to 4 (Completely) 
FTA 
Group 
Suture 
Group 
Q1) How well do you like the appearance of your eyes? 
       0 (Not at All) to 4 (Completely) 
2.6 (1.2) 2.7 (1.6) 
Q2) Would you like to surgically alter the appearance of your eyes?          
      0 (Completely) to 4 (Not at all) 
3.4 (0.8) 3.0 (1.7) 
Q3) Do you feel like the appearance of your eyes makes you look tired? 
       0 (Not at All) to 4 (Completely) 
3.3 (0.8) 3.1 (1.3) 
Q4) How much do you feel your friends and loved ones like the 
appearance of your eyes? 
       0 (Always) to 4 (Never) 
2.9 (0.9) 2.8 (1.6) 
Q5) Do you feel the current appearance of your eyes limits your social 
and professional activities?    
       0 (Not at All) to 4 (Completely) 
3.5 (0.7) 3.3 (0.9) 
Q6) How confident are you the appearance of your eyes is the best that it 
can be?        
      0 (Definitely) to 4 (Not al all) 
2.9 (0.9) 2.6 (1.5) 
   
Mean Score (Maximum score = 24) 18.6 (4.0) 17.4 (8.3) 
Total Score (Percentage of maximum) 76.8% 74.4% 
( ) = Standard deviation
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3.5 Summary 
In summary the blepharoptosis surgery identified a lower proportion of success in the FTA group as 
defined by eyelid measurements and the photographic analysis. Patient satisfaction was similar in the 
two groups and was not related to failed objective measurements. A summary of the results is shown 
in the table 27 below. 
 
Table 27 Summary of Trial Results for Blepharoptosis Surgery 
 Outcome Measure FTA   Vs   Suture Group 
Statistical Test & Significance 
Surgical 
Outcomes 
Eyelid Measurements: MRD, 
Severity, Difference, Levator 
function 
Difference to contralateral eyelid 
 
t-test, chi-squared test 
No difference  
Worse in FTA group (p=0.043)  
  
 
Successful Outcome Measures: 
MRD, Interlid MRD, Redo, 
Complete & Partial Success  
 
t-test 
No difference  
 
 
Complications: Symptoms, skin 
closure, generalized 
chi-squared test 
No difference 
Photographic 
Outcomes 
Photograph analysis: ptosis, scar 
and overall score 
Mann-Whitney test 
Worse in FTA group for ptosis and 
overall score (P=0.0471) 
Patient 
Satisfaction 
Outcomes 
Patient Satisfaction Outcomes chi-squared test 
No difference 
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4.0 Blepharoplasty Results 
The patients diagnosed with dermatochalasis without ptosis underwent upper eyelid blepharoplasty 
with randomization for skin closure to the FTA and suture groups. The defined outcomes were 
similarly to those of the blepharoptosis surgery with assessment of surgical outcomes, photographic 
scores and patient satisfaction.  
 
4.1 Patient Demographics 
A summary of the demographic information for the two groups is show in the table 28 below.  The 
ages of the patients, gender, proportions of unilateral cases, race and follow-up period were similar in 
the two groups (p>0.05).   
 
Table 28 Demographic Information for Blepharoplasty patients 
 FTA Group Suture Group 
Number of Patients 15/32 (47%) 17/32 (53%) 
Age  
   Mean 
   Median 
   Range 
 
58 
58 
50-67 
 
55 
68 
45-86 
Proportion of Males 9/15 (60%) 6/17 (70%) 
 Proportion of Bilaterals 15/15 (100%) 13/17 (76%) 
Race 
   Caucasian 
   Afro-Caribbean 
   Asian 
 
12/15 (70%) 
0/15 (0%) 
3/15 (30%) 
 
12/17 (71%) 
1/17 (5%) 
4/17 (24%) 
Follow-up Period (months) 
   Mean 
   Median 
   Range 
 
13 
11 
8-19 
 
8 
8 
6-18 
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4.2 Surgical Outcomes 
Following blepharoplasty surgery there was a small and non-significant increase in the marginal 
reflex distance, which is consistent with the upper eyelid blepharoplasty surgery.  In addition the 
difference in eyelid height compared to the contralateral side was similar in both groups.  
 
Table 29 Surgical Pre-Operative and Post-Operative (6-months) Measurements for 
Blepharoplasty Patients 
  FTA Group Suture Group Statistic Test 
(t-test) 
Pre-
operative 
Margin Reflex Distance 
(mm) 
2.9 (0.8) 2.3 (1.2) 
t = 1.558, 
p=0.067 
Post-
operative 
(6-months) 
Margin Reflex Distance 
(mm) 
3.5 (1.1) 3.1 (1.2) 
t = 0.894, 
p=0.194 
Difference to 
contralateral eyelid 
(mm) 
0.7 (0.5) 0.4 (0.5) 
t = 0.660, 
p=0.278 
( ) = Standard deviation
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The blepharoptosis defined criteria for success were also use for the blepharoplasty patients. Although 
the success rates were around 90% following upper eyelid blepharoplasty, as the surgery did not 
involve the upper eyelid levator complex a higher success rate may have been anticipated. On 
evaluation of the individual patients, all three eyelids the FTA group that had a marginal reflex 
distance of less than 3mm in the post-operative period, had borderline blepharoptosis preoperatively.  
Only one of the patient in each group went onto have redo surgery.  
 
Table 30 Successful Outcomes for Blepharoplasty surgery 
  FTA Group Suture Group Statistic Test 
(Chi-Squared) 
1 Margin reflex distance ( 3-5mm) 90% (27/30) 83% (25/30) χ = 0.7448, 
P>0.05 
2 Interlid marginal reflex difference 
(≤1mm) 
93% (14/15) 94% (15/16) - 
3 Redo surgery (No) 97% (29/30) 97% (29/30)  - 
 Complete success (All criteria met) 83% (25/30) 80% (24/30) χ = 0.739, 
P>0.05 
 Partial success (One or more of the 
measurements was outside the 
defined range) 
100% (30/30) 100% (30/30) - 
 
The complication rates from the upper eyelid blepharoplasty were similar in the two groups in the 
postoperative period.  There was a higher level of irritation in the suture group (n=4) although the 
difference was statistically non-significant compared to the FTA group (n=1).  In the FTA group one 
patient had early dehiscence of the wound in the early post-operative period, this was managed with 
the insertion of sutures under local anaesthesia. The dehiscence was attributed to the early learning 
curve, a more cautious approach to confirmation of wound adhesion at the end of surgery was adopted 
and no further cases of dehiscence occurred. 
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Table 31 Symptoms following Blepharoplasty Surgery 
  FTA Group Suture Group 
Symptoms 
Discomfort/ Pain 0 0 
Pruritus/ Irritation 1 4 
Other (Watering, Discharge) 0 0 
Total  3% (1/30) 13% (4/30) 
 
 
Table 32 Complications from Blepharoplasty Surgery 
 Complication FTA Group Suture Group 
Low 
Morbidity 
Inflammation/ Swelling 0 1 
Granuloma 0 0 
Infection 0 0 
Dehiscence 1 0 
Ecchymosis/ Haematoma 0 2 
Absent skin crease 2 0 
Scarring (Prominent skin crease) 0 0 
Exposure Keratopathy 0 0 
Other* 3 0 
    
High 
Morbidity 
Necrosis 0 0 
Anaphylaxis 0 0 
Reduced visual acuity 0 0 
Systemic infection 0 0 
    
Total Complications 20% (6/30) 10% (3/30) 
* Excess FTA removed 1-week post-operatively
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4.3 Photographic Outcomes 
An example of the pre and postoperative photographs are show in the subsequent figures.  
Figures 17 and 18 shows an early postoperative photograph of the patient in primary gaze and down 
gaze, one week after skin closure with FTA.   
Figures 19 and 20 shows the same patient in the 3rd postoperative week and the patient has a good 
symmetrical appearance.  
Figure 21 shows a high magnification of the skin crease 1-week after skin closure with FTA. The 
skin crease is difficult to see without magnification there are no marks, minimal inflammation or 
ecchymosis.  
!
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Figure 17  Blepharoplasty Post-Operative Photograph Week 1 in Primary Gaze 
 
 
Figure 18  Blepharoplasty Post-Operative Photograph Week 1 in Down Gaze 
 
!
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Figure 19  Blepharoplasty Pre-Operative Photograph Week 3 in Primary Gaze 
 
 
Figure 20  Blepharoplasty Pre-Operative Photograph Week 3 in Down Gaze 
 
 
!
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Figure 21  Blepharoplasty High Magnification Photograph Week 1 
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Outcomes for the photography analysis were similar in the FTA group (Total Score=2.4 ±2.4) 
compared to the suture group (Score 3.5 ±2.1).  The surgical outcome measures are summarized in 
the Table 33 below. 
 
Table 33 Photographic Outcomes for Blepharoplasty 
  
FTA Group 
Score 
Suture Group 
score 
Statistic 
Test  
(Mann-
Whitney) 
Eyelid 
Evaluation 
Superior lid crease 
Eyelid contour 
Superior sulcus 
Compared to pre-op 
Step-off border (borders not in same 
plane) 
1.3 (1.3) 2.3 (2.1) 
MW = 63.0 
P = 0.1658 
Scar 
Evaluation 
Contour irregularity (wrinkled skin 
near wound) 
Margin separation (gap between sides)  
Edge inversion (wound not everted) 
Excessive inflammation (swelling, 
oedema) 
Overall cosmetic appearance 
1.2 (1.1) 1.3 (0.5) 
MW = 58.5 
P = 0.2932 
Total Score 
 
2.5 (2.4) 3.5 (2.1) 
MW = 46.5 
P = 0.3598 
Score 0 = Normal, Score 1 = Abnormal, ( ) = Standard deviation 
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4.4 Patient Satisfaction Outcomes 
Patient satisfaction as evaluated by the validated questionnaire was similar in the two groups (FTA 
group score=21.9 and suture group score=20.1) and the majority of patients were satisfied in both 
treatment groups.  
Table 34 Patient Satisfaction Outcomes for Blepharoplasty Surgery 
Questions/ Each question scored from  
 
FTA Group Suture 
Group 
Q1) How well do you like the appearance of your eyes? 
       0 (Not at All) to 4 (Completely) 
3.7 (0.8) 3.1 (0.7) 
Q2) Would you like to surgically alter the appearance of your eyes?          
      0 (Completely) to 4 (Not at all) 
3.4 (1.5) 3.6 (0.8) 
Q3) Do you feel like the appearance of your eyes makes you look 
tired? 
       0 (Not at All) to 4 (Completely) 
4.0 (0.8) 3.7 (0.5) 
Q4) How much do you feel your friends and loved ones like the 
appearance of your eyes? 
       0 (Always) to 4 (Never) 
3.0 (0.8) 3.1 (0.7) 
Q5) Do you feel the current appearance of your eyes limits your social 
and professional activities?    
       0 (Not at All) to 4 (Completely) 
4.0 (0.7) 3.7 (0.9) 
Q6) How confident are you the appearance of your eyes is the best that 
it can be?        
      0 (Definitely) to 4 (Not al all) 
3.7 (0.9) 3.0 (1.5) 
   
Mean Score (Maximum score = 24) 21.9 (3.0) 20.1 (2.7) 
Total Score (Percentage of maximum) 91.1% 83.9% 
( ) = Standard deviation
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4.5 Summary 
In summary the outcomes of the upper eyelid blepharoplasty surgery were similar in the FTA and 
suture groups as defined by the surgical outcomes, photographic outcomes and patient satisfaction 
outcomes. A summary of the results is shown in the Table 35 below. 
 
Table 35 Summary of Trial Results for Upper Eyelid Blepharoplasty Surgery 
 Outcome Measure FTA vs Suture Group 
Statistical Test & Significance 
Surgical 
Outcomes 
Eyelid Measurements: MRD, 
Severity, Difference, Levator 
function 
t-test, chi-squared test 
No difference  
Successful Outcome Measures: 
MRD, Interlid MRD, Redo, 
Complete & Partial Success  
t-test 
No difference  
Complications: Symptoms, skin 
closure, generalized 
chi-squared test 
No difference 
Photographic 
Outcomes 
Photograph analysis: ptosis, scar 
and overall score 
Mann-Whitney test 
No difference 
Patient 
Satisfaction 
Outcomes 
Patient Satisfaction Outcomes chi-squared test 
No difference 
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5.0 Discussion & Conclusion 
5.1 Discussion 
Few high quality studies have evaluated the use of FTAs for skin closure and this randomized control 
study compared the use of FTAs compared to conventional suture closure of skin for blepharoptosis 
and upper eyelid blepharoplasty.  Previous studies have shown limited effective evaluation of surgical 
outcome following eyelid surgery and this research project utilized three independent evidence-based 
measures for the evaluation of eyelid surgery outcomes.  
   
Blepharoptosis Surgery 
The blepharoptosis patients in the study had a significantly lower rate of success in the FTA group 
with respect to the contralateral eyelid measurements and the photographic outcome scores.  Although 
the procedure to elevate the eyelid was identical in the two groups, the results suggest the FTA may 
have affected the eyelid height leading to a lower outcome.  The FTA was placed at the dermal edges 
anterior to the eyelid levator complex, and some FTA may have made direct or indirect contact with 
the levator mechanism resulting in a change in the eyelid height. Although not of statistical 
significance, the skin crease was on average 1.2mm higher in the FTA group. 
 The overall complication rates were similar in the Tisseel FTA group and the suture group.  
One patient in the suture group was complicated with a suture related granuloma. The granuloma was 
managed conservatively with removal of residual suture and topical antibiotic and anti-inflammatory 
ointment, the patient went on to have a satisfactory result with good surgical outcome.  Twice as 
many of the patients in the suture group reported postoperative irritation compared to the FTA group. 
The irritation from the skin sutures did resolve on their removal.  The literature had reported reduced 
haemorrhage following the use of FTAs in facial surgery.  In this study there was no difference in the 
recorded ecchymosis between FTA (n=2) and suture (n=2) groups and no cases of haematoma 
formation in either group.  
Transcutaneous levator repair is one of the commonest treatments for involutional ptosis.  
Although the technique is relatively standardized there is recognized unpredictability of postoperative 
eyelid height.  This study identified a complete success rate of 63% in the FTA group and 77% in the 
suture group, which is comparable with published results, the BOPSS national ptosis audit had a 57% 
success rate (Scoppettuolo et al., 2008).  The proportion of success rates based on MRD was 69% in 
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the FTA group and 81% in the suture group, again comparable with the 71-74% reported in the 
literature (Berlin and Vestal, 1989, Meltzer et al., 2001). 
 Previous publications evaluating the use of FTAs on eyelid surgery have had considerable 
variability in patient selection, surgical technique and surgical outcome (Table 9).  The variability in 
these studies makes comparisons between FTA and non-FTA skin closure difficult and compromised 
with confounding factors.  This study reduced the potential for confounding factors with defined 
inclusion and exclusion criteria.  Randomization of the patients to the FTA and suture groups for skin 
closure reduced the potential for selection bias, which is a common weakness of the majority of FTA 
publications. The downside of strict criteria for entry into the study was the reduced numbers of 
patients in the study. The complications of eyelid surgery such as granuloma formation and infection 
were relatively uncommon and the impact of reduced patient numbers is relatively few complications 
in each group and limitation in the statistical findings. 
 On evaluation of the photographic outcomes for blepharoptosis surgery, the outcomes were 
statistically worse for the blepharoptosis scores in the FTA group. This is consistent with the eyelid 
measurements, and finding that the FTA group had more measurements outside the defined success 
for MRD (3-5mm) and interlid measurements (≤1mm) that corresponds to increased eyelid 
asymmetry on photograph analysis.  The photographic evaluation of the scars in the two groups was 
similar. Although some studies had identified increased wound healing and the potential for increased 
scarring in the suture closure group as a result of point fixation this was not reflected in the results of 
this study.   
 On comparison of the three different outcome measures there was consistency between the 
objective eyelid measurements and the standardized evaluation of postoperative photographs. With 
both outcome measures the suture group outcomes were statistically better than the FTA group.  The 
third outcome measure that evaluated patient satisfaction from a validated questionnaire was similar 
in the two groups.  On evaluation of the individual patient satisfaction scores there was no pattern 
between success rates of surgery as defined by eyelid measurements and patient satisfaction.  This 
finding is consistent with studies that highlight the importance of patient expectation in the 
preoperative assessment of patients and highlights that surgical success by eyelid position and 
appearance may not necessarily result in favourable patient satisfaction.   
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Blepharoplasty 
In the blepharoplasty groups of patients there was no statistical difference in the outcomes between 
the FTA and suture groups.  Blepharoplasty is a common surgical procedure and post-operative 
symmetry, wound healing and aesthetic appearance are all important for a successful result.  Skin 
closure following upper eyelid blepharoplasty may be challenging as the upper eyelids are mobile and 
skin closure is under tension compared to lower eyelid blepharoplasty and these perpendicular forces 
impact post-operative healing (Greene et al., 1999, Mommaerts et al., 1996).  The majority of studies 
that have evaluated tissue adhesive skin closure have been retrospective and highlighted advantages of 
the FTA technique (Mandel, 1992) with proposed improvements including wound healing and 
reduced suture related complications including cysts, granulomas and scars.  However our study 
found complications in both groups to be rare and transient. There were 4 eyelids with irritation in the 
suture group compared to only one in the FTA group and these symptoms resolved on removal of the 
sutures.  There was one case of dehiscence of the wound in the FTA group, this was early in the study 
and attributed to the learning curve of the technique and the patient went on to have a satisfactory 
result with good surgical outcome. Overall the complications were similar between the FTA and 
suture groups.  
 The photographic analysis showed good outcomes that were similar in both groups.  The 
overall scar formation was similar in both groups including inflammation, irregularity and cosmetic 
appearance. Anecdotally the wound healing in the FTA group was fast and resulted in minimal 
recovery time, as illustrated in Figure 19, in some patients there was minimal evidence of surgery at 
1-week post surgery.  
 The patient satisfaction outcomes were similar in both the FTA and suture groups with both 
groups having high levels of patient satisfaction, 91% in the FTA group and 84% in the suture group.  
The results are consistent with those published for blepharoplasty surgery with the same patient 
satisfaction questionnaire (Mean satisfaction = 90%; (Alsarraf et al., 2001). The proportion of 
satisfaction was higher in the blepharoplasty patients than in the blepharoptosis patients which is 
consistent with the literature, and may be a result of the increased unpredictability of postoperative lid 
height in the blepharoptosis patients. 
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FTA 
There are theoretical advantages of the use of FTA in patients with increased risk of haemorrhage 
including those with drug induced clotting abnormality (e.g. aspirin, NSAIDs) as FTAs are 
independent of platelet factors, haemorrhage can be controlled with FTA use (Mandel, 1992).  In this 
study there were relatively few complications relating to haemorrhage following blepharoptosis or 
blepharoplasty surgery, and the FTAs did not offer an advantage with respect to haemorrhagic 
complications in this study.    
The FTA is relatively straightforward to use, including the preparation of the FTA and its 
application.  The adhesive sets quickly once applied and had good tensile strength at the end of the 
procedure.  As with most surgical techniques there is a learning curve towards using the FTA 
effectively.  In this study one patient had wound dehiscence and presented within a week of surgery, 
this was thought to be a result of inadequate FTA application during the procedure and confirmation 
of effective wound adhesion at the end of surgery.  This case was early in the study and believed to be 
a consequence of the learning curve of FTA application.  Other authors have similarly expressed a 
learning curve associated with the technique, Grossman et al had five cases (4.7%) localized 
ischaemic necrosis following rhytidectomy that was explained by overzealous undermining, flap 
tension and cautery for haemostasis in early cases (Grossman et al., 2001).  Thick areas of sealant 
may cause ischaemia that act as a barrier limiting normal capillary growth and oxygenation of tissues.  
There were no cases of necrosis in our study.  FTA has advantages in triggering the clotting cascade 
thereby reducing haemorrhage and the likelihood of haematoma formation, is not however a 
replacement for meticulous surgical technique as the adhesive is ineffective if the skin surfaces were 
not dry.  
There are two important complications that have been associated with the use of FTAs; the 
transmission of infection and allergic reaction (Kawamura et al., 2002, Oswald et al., 2003).  
Although there were no serious adverse reactions associated with the use of FTAs in this study, these 
complications are very rare yet with important implications.  In over a decade of use of FTA in a 
range of clinical specialties, the only report of transmission of infection is of parvovirus B19 
(Kawamura et al., 2002). Although extensive screening and processing is conducted to prevent the 
risk of infection, the risk cannot be completely eliminated. A recombinant FTA is in development and 
long-term the use of recombinant formulations of FTAs would eliminate this infection risk.  Allergic 
or anaphylactic reactions to FTAs are very rare, and are thought to have resulted from the use of 
bovine products such as bovine derived aprotinin in the early manufacture of the FTAs. The modern 
day manufacture has eliminated this product with the use of synthetic aprotinin.  In addition the cases 
of anaphylaxis have occurred with sensitization to the sealant after repeated use, the use of FTA to 
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close central spinal fluid leaks in association with intracranial hypertension (Schievink et al., 2008, 
Shirai et al., 2005). The cases of anaphylaxis were thought to have resulted from inadvertent 
intravascular injection of the FTA during percutaneous injection into the epidural space (Schievink et 
al., 2008). There are no reported cases of anaphylaxis following relative superficial use of FTAs for 
soft tissue or skin closure. 
 Cost-effectiveness is an important aspect in the delivery of healthcare and one potential 
disadvantage of the use of FTAs for skin closure is the additional cost of FTA purchase relative to 
sutures.  In this study the FTA group were assessed at 1-week post surgery, to enable comparison with 
suture group.  The additional out-patient appointment for suture removal could be avoided in the FTA 
group which would make the use of FTAs more cost-effective.  A number of studies that have looked 
at skin closure with tissue adhesives have identified a shorter operating time compared to suture skin 
closure (Mommaerts et al., 1996).  This study did not evaluate surgical time, it was noted that the 
preparation of the FTA including warming, mixing and loading of the FTA takes both resources and 
expertise.  Since this study was completed, Baxter had developed a frozen ready-to-use product that 
required no preparation time.  
 
Summary 
• Avoid the use of FTAs in blepharoptosis cases: FTAs effects eyelid height and outcomes 
were not as successful compared to suture closure of skin 
• The use of FTAs for skin closure following upper eyelid blepharoptosis surgery is comparable 
in effectiveness with suture closure 
• FTAs promote rapid healing of the wound, often barely visible at 1-week post surgery 
• Minimal complications occur with the use of FTAs or sutures for upper eyelid blepharoplasty 
• Increased cost of FTA purchase, counterbalanced by savings on suture-removal appointment  
• Theoretical risk of infection and allergy remain with the use of both human and bovine 
components of FTAs 
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5.2 Recommendations 
The conventional closure of skin with sutures for blepharoptosis surgery is recommended as the 
outcomes from this study suggest that the use of FTA skin closure has a less favourable outcome.  The 
use of FTAs or suture have good outcomes following upper eyelid blepharoplasty, and there may be 
an increased rate of healing in the FTA group (Figure 17).   
The use of several eyelid measurements to determine operation success (as devised by the 
BOPSS ptosis audit) is comparable with “blinded” observer evaluation of standardized photographs 
following eyelid surgery.  The results of the patient satisfaction questionnaire were independent with 
the eyelid measurements and photographic outcome measures.  Patient satisfaction is an essential 
aspect of eyelid surgery and the findings in this study suggest further evaluation of individual 
patient’s expectation would be useful to determine their influence on postoperative satisfaction. 
 
5.3 Limitations of Study  
The eyelid height following blepharoptosis surgery may be inconsistent, with an 
unpredictable postoperative upper eyelid height, and a relatively high reoperation rate.  Variability can 
result from a variety of factors including patients’ demographics and gender, surgical methodology 
and surgeon.  Despite identical surgical technique, surgery and perioperative management, outcomes 
are not predictable. This study aimed to minimize the variability with inclusion and exclusion criteria.  
A larger number of cases would have added further validity to the statistical power.  The clinical part 
of this study took over 2-years to complete, and a drawback of the inclusion and exclusion criteria that 
reduced the confounding bias was reduced patient entry to the trial. With the potential for variability 
of surgical technique with different oculoplastic consultants, this trial was limited to the patients seen 
under the care of an individual consultant, where the surgical technique was consistent and less 
subject to the variability that would result from a multi-surgeon trial.  
In this study, histological analysis through biopsies of the two groups at different 
postoperative stages wound have added further information on wound healing.  However there are 
ethical considerations as tissue biopsies in these patients would be an additional and avoidable 
procedure that may have led to complications e.g. scarring, delayed healing.  
This study may be limited owing to the learning curve associated with the use of the FTAs, 
however unsatisfactory surgical outcomes were not seen in larger quantity in the early period of the 
trial.  An optimal comparison of post-operative lid surgery would involve randomization of one site to 
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suture and the other to FTA skin closure, however this was considered to be unethical as it may 
introduce asymmetry.    
 
5.4 Future Research 
The use of FTAs in clinical practice has continued to increase, and with this there have been 
improvements in the reported effectiveness, reduction in costs and complications in surgical practice. 
The combination of FTAs with the use of stem cells and antibiotics offers long-term physiological 
advantages in reconstruction and eyelid procedures (Marone et al., 1999, Kram et al., 1991a).  One of 
the principal limitations of the current FTA products is their use of human donor tissue and risk for 
infection, the development of recombinant non-donor FTA offers elimination of the potential risk and 
is currently under development.  In addition the use of a laser activated adhesive has been trialled, the 
laser causes cross-linking of a hyaluronic acid compound, with the potential use for closing corneal 
incisions or injuries (Kalayci et al., 2003).  
The need for standardized and validated tools for measuring PROMs in oculoplastic surgery 
has been highlighted by the recent Department of Health.  Following on from this research project, we 
plan to develop further measures for the evaluation of oculoplastic procedures by further research and 
clinical networks. 
 Tisseel FTA components are made from human plasma and blood collected from screened 
transfusion centres across the USA and some European countries.  Plasma donors undergo screening 
for the presence of known viruses and viral markers and components are subjected to virus 
inactivation process.  Although no cases of the transmission of infectious diseases has been reported 
in the literature the transmission of infective agents cannot be totally excluded (Saltz, 1992).  The 
development of recombinant fibrinogen may lead to eventual elimination of infection risk (Chan and 
Boisjoly, 2004, Mandel, 1990) . 
Since the completion of this study, the applications of FTAs have continued to grow in 
clinical practice.  Baxter have developed further FTA related products including a pre-prepared frozen 
FTA product that required no preparation or mixing process, this may become the product of choice in 
surgical practice in the future. Although in some countries Baxter has chosen to replace the bovine 
aprotinin with a recombinant protein, the company has no plans to change the bovine aprotinin in the 
UK manufacturing process in the short-term future.   
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5.5 Conclusions 
The eyelids have an important functional role in maintaining good visual acuity, involutional changes 
with increasing age may result in compromised function. Eyelid surgery may be essential to restore 
normal anatomy and function to the eyelids. There are numerous complications that may result from 
eyelid surgery and techniques that propose improved patient morbidity require systematic evaluation 
for both effectiveness and safety.  
 Few high quality studies have evaluated the use of FTAs for skin closure and this research 
project evaluated the use of FTAs in two randomized control studies of blepharoptosis and upper 
eyelid blepharoplasty.  The study suggests that sutures should be used for skin closure following 
blepharoptosis repair, as FTAs may detrimentally impact surgical outcome.  This study supported the 
use of specific eyelid measurements and the evaluation of standardized photographs as outcome 
measures for eyelid surgery.  Further evaluation of patient satisfaction in surgical assessment is 
required as this was found to be independent of both eyelid measurements and photographic analysis.  
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6.0 Appendices 
6.1 Appendix 1- Local Research Ethics Committee Form 
ST MARYS LOCAL RESEARCH ETHICS COMMITTEE 
Mailbox 121, St Marys Hospital, Praed Street, London W2 1NY 
Tel: 020 7886 6514  Fax.1529  Email: Ros.Cooke@st-marys.nhs.uk 
DATE SUBMISSION is sent to LREC office…………………………… 
 
1.           FULL TITLE OF PROJECT:  
A randomised prospective study to evaluate blepharoplasty skin closure by tissue adhesive in 
comparison with conventional suturing techniques. 
 
 What do you regard as the most important ethical issue that necessitates review of your project 
by the LREC? 
Approval of tissue adhesive use for skin closure in blepharoplasty. 
Is the research being done at other centres?     NO 
If YES, where else is it being done? 
 
Is St Marys the Lead Centre?          YES    
If NO, who is the lead centre?    
 
Main research question:    
Identify the advantages of blepharoplasty skin closure using tissue adhesive over conventional 
suturing techniques. 
 
Brief methodology:  
1. Pilot Study of 10 patients to identify number of patients required for the prospective 
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randomised control study. 
2. Entry to trial. Patients will be assessed according to a clearly defined protocol 
incooperating both inclusion criteria, exclusion criteria, patient information leaflet 
and written consent. 
3. Randomization of patients to tissue adhesive and suturing skin closure groups. 
4. Post operative assessment of both all patients at 1 week, 3 weeks and 2 months. 
5. Post operative assessment of by standardized photographs and patient satisfaction. 
 
Proposed start date:                2/2003 
End date:                                   10/ 2003 
 
Number of participants/subjects in research:  
     Pilot study of 10 patients.  
     Prospective randomized control study, patient no. determined by pilot study. 
 
Brief outcome measure description:   
1. Standardized photographs. 
2. Patient satisfaction. 
 
Name/address/tel no. of Drug Company sponsor (if applicable): 
Baxter Healthcare Ltd,  
Bioscience, Wallingford Road, Compton, Newbury, Berks, RG20 7W 
Tel. No. 01635 206 140 
 
Amount be granted by drug company: 
 
 
 
2. INVESTIGATORS 
Principal Investigator(s): Miss Jane Olver and Sheng Lim 
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Name              Signature     Designation 
All other Investigator(s): D Julian De Silva and Doris Zuercher 
Name              Signature     Designation 
Head of Dept/consultant/GP/Community Physician, etc, in overall charge if different from 
above: Miss Jane Olver     
Name              Signature     Designation 
Name, address, tel. No, fax No & Email of investigator to whom all correspondence will be sent: 
Miss Jane Olver, Consultant Oculoplastic Surgeon 
Western Eye Hospital, London, NW1 5YE 
Tel. No. 0207 886 3265 
                       
3. AIMS OF PROJECT: 
This study aims to compare the success rates of skin closure following blepharoplasty surgery, by 
tissue adhesive versus conventional suturing techniques.   
 
 
4. BACKGROUND OF PROPOSED STUDY:  
Blepharoplasty is one of the most commonly performed functional as well as cosmetic 
ophthalmic plastic surgical procedures. The operation may be used to remove skin and lid obstruction 
of the visual field and to remove involutional change in the eyelids secondary to ageing.  
The procedure is most commonly performed under local anaesthesia as a day case procedure. 
The excess skin and skin crease are first marked. An incision is made through the marked skin and the 
skin and underlying orbicularis muscle excised as a single crescentic flap. The orbital septum is 
identified and opened. The fat pads visualized and excised with caution to maintain haemostasis. 
Sutures are then placed in skin, muscle and levator aponeurosis to form the eyelid skin crease. The 
skin is conventionally closed by suturing technique. Sutures are place along the length of the 
blepharoplasty wound. Sutures cause an individual tissue healing response and variable scar 
formation. Patients attend outpatients at 1 week for suture removal, which is an uncomfortable 
procedure. Patients are then seen for further follow up at 3 weeks and 2 months. The patients are 
assessed by lid measurements and photography. 
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We propose the use of a tissue adhesive to close the skin following blepharoplasty. The 
adhesive will be applied as in conjunction with the manufacturing guidelines to both surfaces of the 
wound, which are then gently opposed to allow sealing. The adhesive has been used in a number of 
other oculoplastic procedures such as; entropion skin closure, skin transplants, fixation of orbital 
implants following enucleation and reconstruction of lacerated lacrimal canaliculi. The use of tissue 
adhesive will reduce the need for 1 week postoperative suture removal, decrease the length of 
blepharoplasty operating time and indirectly may reduce waiting list time. Tissue adhesive is likely to 
generate less inflammatory healing response and may improve the aesthetic appearance. In addition, 
tissue adhesive may improve patient satisfaction as a combination of these factors. 
To date, there have been no randomised prospective comparative studies comparing the use of 
tissue adhesive and conventional suturing in blepharoplasty skin closure. We have chosen to compare 
these two techniques and determine whether there is a significant difference between these two 
treatments using a carefully designed study. A multicenter prospective randomised comparative study 
design appears to be the best way to answer this question. 
 
References. 
Fibrin sealant in Ophthalmic plastic and Reconstructive surgery. FJ Steinkogler, A Kuchar; Fibrin 
sealing in surgical and nonsurgical fields. Springer-Verlag, Berlin-Heideelberg 1994. 
 
 
5. DESIGN OF STUDY:    
Give a brief description of what will be done and how it differs from normal practice. 
1. Entry to trial, according to inclusion criteria. 
2. Randomization to suturing and tissue adhesive groups. 
3. Surgery; the patients will undergo the same blepharoplasty procedure. Only the skin closure will 
differ. The patients will either undergo suture skin closure or tissue adhesive closure. 
4. All patients will be followed up at 1 week, 3 weeks and 2 months. The sutured skin closure groups 
will have skin sutures removed at 1 week. 
5. All patients will be assessed in outpatients according to a standardized protocol and patient 
satisfaction. 
 
6. POTENTIAL BENEFITS AND HAZARDS:  If the patient is to be given a placebo or to 
be deprived of active treatment, or if the patient’s regular treatment of known efficacy is 
to be changed for the purpose of the study, describe the justification for these intentions.   
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For questionnaire studies, state what steps are to be taken to ensure reliability and to 
minimise anxiety or embarrassment.   
No patients will be deprived of treatment or given a placebo in this study. 
 
7. LOCATION OF STUDY: 
 
a. Laboratory/Hospital/other: 
Western Eye Hospital, London, NW1 5YE 
Charring Cross Hospital, Fulham Palace Road, London, W6 8RF 
 
b. Name & address of responsible organisation if not St Mary’s NHS Trust, or ICSM 
(Remember you need the approval of the establishment before starting the research) 
 
8. RECRUITMENT OF SUBJECTS:      
Patients presenting to the participating hospitals requiring blepharoplasty and fulfilling the inclusion 
criteria will be invited to take part in the study. 
 
a. Will they be patients, staff, students or other volunteers? 
Patients. 
 
Record inclusion and exclusion criteria.  
 
Inclusion Criteria 
1. Patients requiring blepharoplasty procedure. 
2. Informed consent obtainable. 
3. Patient clinical follow up 12 months after surgery. 
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Exclusion Criteria 
1. Previous blepharoplasty surgery that has failed requiring redo surgery. 
2. History of previous lid surgery. E.g. Tumour excision, ectropion, entropion. 
3. Complicated blepharoplasty requiring multiple operations or other procedures. E.g. Reconstruction. 
4. Patients with only one functional eye. 
5. Patients medically unfit for surgery.  
 
Record any ethnic or social class implications. Nil 
 
How many will be recruited? To be calculated following pilot study. 
How is recruitment to be achieved? 
Patients requiring blepharoplasty procedure from the oculoplastic clinics at the participating hospitals 
who meet the entry criteria will be invited to take part in this study. If they agree, they will be entered 
into the study and randomised. A standardised pre-operative assessment form will be completed, 
written informed consent obtained and a patient information sheet given to the patient. 
 
Will medical/nursing staff or students be involved as volunteers?        
No 
 
b. If recruiting patients who are not your direct clinical responsibility, has the permission 
of the consultant in charge or the co-ordinator of research in your patient group been obtained?
  
Not Applicable 
 
Name                                                                Signature 
c. Is the patient’s GP to be consulted over an individual’s recruitment?     
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YES  
 
 At what stage will the GP be informed? 
Entry to trial. 
 
 Do you intend to send the GP a copy of the patient information sheet? 
YES 
 
 If you don’t intend to inform the GP, state why not: 
 
d. Will recruits be paid an honorarium?           NO 
If YES:   how much? 
 
e. Will travelling expenses be reimbursed:          NO 
              If NO please give reasons 
Travelling to and from hospital for both surgery and follow up appointments remains unchanged from 
conventional surgical management of blepharoplasty. No funding available for patient travelling 
expense. 
 
9. ADMINISTRATION OF STUDY 
 
a. Insurance / Indemnity cover 
 
What arrangements will be in place to cover subjects/patients 
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(If you are unsure about this please contact Donna Twyman, Research & Contract Office, Medical 
School, W2  Ext 020 7594 3664) 
  
b. If this is a drug study, at what stage is this in its evaluation? 
 
c. Is this drug being supplied by a company with a clinical trial certificate in response to 
an investigator with a clinical trial exemption. 
NO 
 
d. If the drug is licensed but being used in a non-licensed context which is not being 
sponsored by the pharmaceutical company concerned, investigators must obtain a DDX from 
the Medicine Control Agency (020 7273 0327/8).  Clinical Research must not be undertaken in 
patients unless a CTX or DDX is in operation. 
NO 
 
Give the Clinical Trial Certificate (CTC) or Clinical Trials Exemption (CTX) numbers if relevant. 
 
e. If this is a company sponsored trial, are the investigators free to publish their results 
(subject to a reasonable period of consultation with the company)? 
 
NO 
 
g. If any form of radiation is to be used (eg. X rays, radioactive isotopes, heat, UV, laser, 
etc) this form must be signed by the Radiation Protection Advisor, or a separate letter attached. 
Not applicable. 
 
Name:         Signature: 
10. SUBSTANCES TO BE ADMINISTERED.   The Committee must be informed immediately 
of any severe or unexpected adverse side effects. 
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a. Please give details of substance to be administered, route, amount, frequency, risks to 
subject and others, and side effects. 
Tisseel adhesive. 
A thin layer of Tisseel adhesive is applied proportional to the wound area. 
The wound is help clamped for 3-5 minutes to allow adequate time for setting. 
Side effects include thromboemoblic complications and allergic reactions. The Tisseel adhesive 
contains extracts of human plasma and although extensively screened , the transmission of infective 
agents cannot be totally excluded. No cases of such transmission have been reported. 
 
11. WHAT WILL BE DONE TO SUBJECTS BECAUSE THEY ARE TAKING PART IN 
THE STUDY? 
Describe briefly under headings below, what will be required of subjects; indicate if anything is 
additional to normal clinical management; indicate discomfort and risk to subject & others. 
 
a. Are any treatments or procedures being withheld, which would otherwise be given? 
NO 
 
b.      Samples to be taken:   NIL 
 
c. Tests to be undertaken:   (Please circle appropriate test and give details) 
 
Photographs-  Standardized to enable a comparison of adhesive and sutures outcomes. 
 
 Biopsies:  NIL 
 
 Anaesthesia:    Local 
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 Other invasions:  NIL 
 
 Non-invasive tests: NIL 
 
 Physical Stress Tests: NIL 
 
 Psychological Tests: NIL 
 
 Psychiatric evaluations: NIL 
 
 Questionnaires: Patient satisfaction questionnaire 
 
 Hospital admissions for purposes of project:   Day case surgery 
 
 Outpatient visits: 1 weeks, 3 weeks and 2 months. 
 
 Describe what results you expect and how they will be analysed. 
The results of blepharoplasty skin closure will be compared between the tissue adhesive and the 
suturing closure techniques. We hypothesize: 
1. Tissue adhesive to reduce operating time for blepharoplasty procedure. 
2. Tissue adhesive to reduce the number of follow up appointments. 
3. Tissue adhesive to improve aesthetic appearance of blepharoplasty result. 
4. Tissue adhesive to improve patient satisfaction. 
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 List discomfort, inconvenience, possible side effects and dangers, untoward signs or 
symptoms. 
We expect discomfort and inconvenience to be unchanged from conventional blepharoplasty surgery, 
and adhesive may reduce discomfort compared to conventional suturing. 
Specific side effects of Tisseel adhesive include thromboemoblic complications and allergic reactions. 
The Tisseel adhesive contains extracts of human plasma and although extensively screened , the 
transmission of infective agents cannot be totally excluded. 
 
 List precautions which are to be taken with regard to above, and what arrangements 
will be in place for medical cover.  If relevant indicate whether patient information sheet will 
include name(s) and phone nos. of investigator(s) to be contacted in the event of unexpected 
reactions of incidents. 
Patients will be monitored during and after surgery for both allergic reactions and thromboemobolic 
complications. Patients will be given specific advice regarding complications and indications to obtain 
medical help. Contact numbers will be provided. 
 
12. OTHER RESOURCES   (Contact your Directorate General Manager to discuss) 
 
a. Will this project make use of hospital resources?  (eg,.  beds, X rays, NMRI, ECGs, 
operating time, blood tests, etc?) 
 
NO 
 
b. List departments / Outpatients / Inpatient involvement 
Outpatient department – 3 Visits 
Photography – 3 Visits 
 
c. How much will they cost? 
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d. Is the cost being met by a research grant? 
 
NO 
 
e. Obtain signatures of approval from head of each department involved 
Name                                                                                                           Signature 
 
f. If a compound/drug/device is to be used/tested as part of the study, state the source of 
funding for its provision. 
Tisseel adhesive, provided by Baxter Healthcare Ltd. 
 
g. Will a questionnaire be used? 
 
YES 
 
If YES, and less than 4 A4 sheets, attach a copy with each form copy.  If questionnaire is standard, 
validated, and / or longer than 4 sheets send 2 copies only. 
 
f. Will a semi-structured interview be used? 
 
NO 
 
!
!
124!
13. HAVE YOU HAD STATISTICAL ADVICE? 
 
YES 
 
a. From whom did you get it? 
 
b. …in preparing the protocol?   NO 
 
c. …in designing the analysis?   NO 
 
d. …in deciding the power of the study and number of subjects needed? 
         YES                                                                                                
 
14. SENIOR NURSE OUTPATIENT / WARD 
The senior nurse should be supplied with a copy of patient information sheet relating to studies on 
patients under her supervision. 
 
a. Do you plan to ensure this is achieved?    YES 
 
 
15. CONFIDENTIALITY 
 
a. What steps will be taken to safeguard the confidentiality of patients’ records? 
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Patient records for the trial will be stored separate to conventional hospital notes in a secure location 
in the Western Eye and Charring Cross Hospitals. Access to the records will be limited to staff 
associated to the study. 
 
b. Is data to be recorded automatically?      
Data is to be recorded according to standardized protocols. These will include both outpatient 
assessments and photographic records. 
 
If non coded information is being collected, provide copy of your data registration form.  It is 
necessary to comply with the requirements of the data if in doubt contact District Data Protection 
Officer (020 7594 5535) 
 
c. If the study is a company sponsored trial, will the company require access to the 
patients’ notes?         YES 
 
If YES provide documentation to the effect that confidentiality will be respected. 
 
16. CONSENT AND PARTICIPANT INFORMATION SHEET 
 
Inadequate or incomprehensible information is the most common reason for delay in projects being 
approved by the LREC.  Information for participants must be fully comprehensible by lay individuals.  
Read the Guidelines carefully and make sure your sheet addresses appropriate headings, eg opt out 
clause, researcher’s name/tel no., invite to do research, risks and benefits, etc. 
 
a. IS CONSENT REQUIRED?          YES 
 
If YES, will consent be:                            WRITTEN – Customised form. 
 
If  WRITTEN  is the LREC Consent form to be used?  If you are customising this form please send a 
copy with each application form copy. 
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If NO, explain why consent is not required, or explain any difficulty that might arise in obtaining 
consent. 
 
c. IS A PATIENT INFORMATION SHEET TO BE MADE AVAILABLE? 
 
YES  /  NO         If YES please enclose a copy with each application form copy. 
Consult the guidelines carefully for necessary headings. 
 
* Ensure this includes statements to the effect:    
* Entry to the study is entirely voluntary 
* Failure to enter, and subsequent decision to withdraw from the study will not effect         
the  patient’s medical care. 
* Paragraph about indemnity cover is included:  (eg. ABPI Guidelines for drug 
sponsored studies) 
* Risks and benefits  
 
 
c. What arrangements will be made for subjects for whom English is not a first language? 
Patients who are unable to comprehend a basic understanding of the English language are not 
appropriate for local anaesthesia technique under conventional suturing or tissue adhesive 
technique. 
 
 
d. Who will obtain consent? 
Doctors directly involved in the project, who have received detailed training in the protocol.  
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e. Will participants be informed of the nature and risks of their participation? 
Patients will be informed of the principles of the trial in a patient information sheet. 
 
 
f. I / we confirm that the following will be placed in the patient’s records and in the case of 
research volunteers these will be held by the named investigator for the study: 
 
*           the signed consent form:    *  patient information sheet:        
Name(s) of those who will be obtaining consent                                       Signature: 
17. PAYMENTS / SPONSORSHIP 
 
a. Are any / all of the investigators in receipt of any payments / sponsorship? 
 
NO 
 
 
b. Who is funding the investigation?    
Baxter Healthcare Ltd. 
 
c. How much money may be provided for this project alone?     Give details, specifying 
whether this funding is part of a larger sum granted for a number of projects. 
 
 
18. WILL THE INVESTIGATOR(S) / DEPARTMENT RECEIVE 
GRANTS/PAYMENTS/SPONSORSHIP FOR THE WORK UNDERTAKEN? 
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YES 
a. How is the money to be spent?   (List major items of equipment, staff, etc) 
Tisseel tissue adhesive kits + Surgical equipment 
Digital Camera + Photography 
Medical Records + Data Storage 
Stationary + Secretarial Time 
 
 
b. Please give details of any other related payments 
 
19. WHAT PROBLEMS MAY HINDER A SUCCESSFUL COMPLETION OF THIS 
STUDY?    (This may include ethical problems that may arise during the course of the project). 
NIL 
 
20. OTHER FACTORS      Please indicate any other factors relevant to approval from LREC. 
 
Please send 11 photocopies of this application form + additional information as specified, to: 
Rosalind Cooke, Mailbox 121, R&D  St Marys Hospital, Praed Street, London W2 1NY 
Tel:   020 7886 6514    fax:   1529 
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6.2 Appendix 2- Patient consent form 
 
Clinical study comparing two types of skin closure following blepharoplasty. (COREC number) 
 
1. This study compares 2 different skin closure techniques; Conventional suture closure of skin and 
tissue adhesive closure. 
 
2. I confirm that I have read and understood the information sheet for patients relating to the above 
study and have had the opportunity to ask questions. 
 
3. I understand that my participation is voluntary and I am free to withdraw at any time, without 
giving reasons, without my medical care or legal rights being affected. 
 
4. I understand that sections of my medical notes may be looked at by responsible individuals from 
within this hospital or from regulatory authorities where it is relevant to my participation in research. I 
give permission to these individuals to have access to my records.  
 
5. I give permission for information which is collected in the above study to be stored both as paper 
and electronic records. I also give permission for this information to be analysed as part of this 
research.  
 
6. I agree to participate in the above study.  
________________________ Signature of doctor obtaining consent 
________________________ Name of doctor 
________________________ Date 
________________________ Signature of patient 
________________________ Name of patient / guardian 
________________________ Date 
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6.3 Appendix 3- Patient Information Sheet 
Patient information sheet : Blepharoplasty study 
 
Thank you for considering participation in the blepharoplasty study. 
 
Purpose of study 
This study compares two surgical techniques in closure of the wound following blepharoplasty. 
 
Why have I been selected ? 
You have an eyelid/ s which requires surgery. Surgery is the only method by which the shape of your 
eyelid may be changed. The surgical method to do this is well established. We would like to compare 
the results of closure of the wound following blepharoplasty. 
 
1. Traditionally the wound is closed using sutures. These sutures are then removed one week after the 
operation.  
 
2. A tissue adhesive is available that can seal the wound in a few minutes avoiding the need for 
sutures and one week suture removal. Tissue adhesive has been used by plastic surgeons for a number 
of years to close skin with good cosmetic results. 
 
The blepharoplasty surgery technique would be unchanged except for wound closure at the end of the 
operation. We would like to find out if there is a difference between the two methods that would 
justify using only one method in the future. There have not been any studies done before comparing 
these methods and the answer would help us determine the best way to close skin following 
blepharoplasty.  
 
Do I have to take part? 
You are not obliged to take part. If you decide to take part, you will be given this information sheet 
and be asked to sign a consent form. The operation is similar to what you would be offered if you 
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were not part of the study. You are free to withdraw at anytime and without giving a reason. If you 
decide not to take part, the quality of your care will not be affected in any way.  
 
What is involved if I decide to take part? 
Half of the patients taking part in this study will be randomised to have one type of surgery and the 
other half to the other. The surgery is normally done under local anaesthetic. Whatever surgery you 
have been allocated to, we will check you eyelid in the clinic at 1 weeks, 3 weeks, and 2 months after 
the operation. If you notice any problems with your eyelid before or between these scheduled visits 
then, you should contact one of your treating doctors.  
 
Are there risks in this operation?  
The risks of the blepharoplasty operation are recurrence, over or under correction, infection and 
inflammatory reaction. This operation is not a new procedure and is very safe, however very rarely 
blepharoplasty may be complicated with blindness. Tissue adhesive has been used for a range of 
plastic surgery techniques and rarely has been complicated by allergy or an increased risk of blood 
clots. The tissue adhesive is made from human blood products and is extensively screened for 
infectious material. No reports of infection spread by tissue adhesive have been reported. 
 
What happens if something goes wrong? 
If you wish to complain about the way you have been treated during the course of the study, the 
normal NHS complaints mechanisms will be available to you. If you are harmed due to someone 
else’s negligence, then you may have grounds for legal action but you may have to pay for it. There 
are no special compensation arrangements attached to this study.  
 
Will information on me taking part in this study be kept confidential?  
All information collected about you during the course of the study will be kept strictly confidential. 
 
What will happen to the results of the study? 
The results of the study will be published after 2 years of you completing your treatment. You will not 
be identified in any report or publication.  
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Who has reviewed the study? 
The research ethics committee of the NHS Trust of your local hospital has reviewed and approved this 
study. 
 
For further information, please contact your own Consultant Ophthalmologist or The Project 
Co-ordinator : 
 
Miss Jane Olver, Consultant Ophthalmologist, 
The Western Eye Hospital 
Marylebone Road, 
London NW1 5YE 
Telephone : 020 7886 3264 
Fax : 020 7886 3259 
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6.4 Appendix 4- Information sheet for the patient’s general practitioner 
 
Blepharoplasty surgery : A comparison of skin closure techniques following blepharoplasty, using 
conventional suturing techniques compared to tissue adhesive. (COREC number)  
 
 
Dear Doctor, 
 Your patient has agreed to participate in the above study. It is a multicentre prospective 
randomised study aimed at comparing the results of suturing and tissue adhesive surgical skin closure.  
 All patients will undergo blepharoplasty in the same manner. Skin closure will be randomized 
to conventional suturing and tissue adhesive. Suture closure requires additional operating time, suture 
removal at 1 week post-operation and may give a variable tissue healing response and resulting scar. 
Tissue adhesive has been utilized for a number of plastic and oculoplastic procedures with favourable 
aesthetic results. However, there have been no randomised controlled prospective studies comparing 
these two procedures.  
 Our study aims to determine whether there is any significant difference in the success rates of 
these two operations. 
 If you have any enquiries about this study, please contact the local Consultant 
Ophthalmologist in charge of your patient or the Project Co-ordinator :  
  
 Miss Jane Olver, 
 Consultant Ophthalmologist, 
 The Western Eye Hospital, 
 Marylebone Road, 
 London NW1 5YE 
Name!:!
Date!of!birth!:!
Hospital!Number!:!
Male!/!Female!
!
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 Telephone : 020 7886 3264 
 Fax : 020 7886 3259 
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6.5 Appendix 5- Operative Record 
 
Operative record 
 
 
 
1. Date:     
 
2. Type of surgery(please circle):   Suture  Vs Adhesive 
 
3. Surgeon (Name and grade) :   
 
4. Study eye (please circle) :   Right /   Left/   Both 
 
5. Anaesthetic :     Local  
 
6. Operative complications (if any):  
 
7. Comments (eg. if procedure or materials different from protocol) 
 
Name!:!
Date!of!birth!:!
Hospital!Number!:!
Male!/!Female!
!
Hospital!:!!!!!(Please!circle)!
!
Western!Eye!Hospital,!London!
Charing!Cross!Hospital,!London!
!
!
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6.6 Appendix 6- Postoperative record 
 
.  
 
1. Date:    
2. Type of surgery(please circle):   Suture / Adhesive 
 
3. Time after surgery (Please circle) :  1 Week/  3 Weeks/ 2 Months 
 
4. Study eye (Please circle):  Right /  Left/  Both 
 
5. Form completed by (Name and grade) :  
 
6. Symptoms (please circle):   
Irritation  Discharge   Pain  Other:  
Stickiness  Foreign body sensation Epiphora 
 
Name!:!
Date!of!birth!:!
Hospital!Number!:!
Male!/!Female!
!
Hospital!:!!!!!(Please!circle)!
!
Western!Eye!Hospital,!London!
Charing!Cross!Hospital,!London!
Raigmore!Hospital,!Inverness!
!
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7. Signs:       
 Right eye Left eye 
Visual Acuity   
Visual Field Testing   
Brow Height   
Margin reflex distance, (upper 
and lower, mm) 
  
 
Position of eyelid crease   
Lagophthalmos   
Cornea (SPK / erosion / 
ulceration / other) 
  
Tear Film/ BUT   
 
8. Postoperative complications (please circle) :  
Ptosis/ Infection / Stitch granuloma / Wound dehiscence / Other (please state):  
 
9. Photographs requested  Yes/ No 
 
10. Result (please circle) : Success / Failure(please state reason for failure):  
 
11. Any other comments (eg. further surgery needed) 
!
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6.7 Appendix 7- Photographic record 
 
.  
1. Date:  
   
2. Type of surgery(please circle):   Suture / Adhesive 
 
3. Time after surgery (Please circle) :  Pre Op/      1 Week/    3 Weeks/     2 Months 
 
4. Study eye (Please circle):  Right /  Left/  Both 
 
5. Photographs taken  by:  
 
6. Photograph standardization:       
 YES /  NO 
Both eyes- primary position  
Both eyes-looking up  
Both eyes-looking down  
  
Close up-incision site  
Close up-opposite side  
 
7. Any other comments  
Name!:!
Date!of!birth!:!
Hospital!Number!:!
Male!/!Female!
!
Hospital!:!!!!!(Please!circle)!
!
Western!Eye!Hospital,!London!
Charing!Cross!Hospital,!London!
!
!
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6.8 Appendix 8- Patient Satisfaction Questionnaire 
  
We would appreciate you completing this form so we can assess your treatment completely and aim 
to improve the oculoplastic service further. Your comments are confidential 
Please circle your choice: 
 
Were you happy with your blepharoplasty surgery?   Yes/ No 
 
Is there any part of the surgery you were not happy with? 
 Prior to operation  Yes/ No 
 Operation   Yes/ No 
 After operation  Yes/ No 
 
1. How well do you like the appearance of your eyes and eyelids? 
Not at all   Somewhat  Moderately  Very much  Completely 
0  1            2             3  4 
2. Do you feel like the appearance of your eyes makes you look tired? 
Completely Very much  Moderately  Somewhat    Not at all 
0  1  2  3  4 
3. How much do you feel your friends and loved ones like the appearance of your eyes? 
Not at all   Somewhat   Moderately   Very much Completely 
0  1  2  3  4 
4. Do you feel the current appearance of your eyes limits your social or professional activities? 
Always  Usually      Sometimes    Rarely      Never 
0  1              2            3  4 
!
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5. How confident are you that the appearance of your eyes is the best that it can be? 
Not at all    Somewhat    Moderately  Very much  Completely 
0  1  2               3  4 
6. Would you like to surgically alter the appearance of your eyes? 
Definitely    Most likely   Possibly    Probably not   No 
0  1  2              3  4 
 
Other Comments regarding your surgery: 
Are there any other ways we could continue to improve the oculoplastic service? 
!
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6.9 Appendix 9- Ethics Approval Letter 
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